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Due to the increased prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) 
has become a major public health problem in the Western world and Asian countries.  
Approximately a third of the general population in the US has NAFLD. NAFLD includes 
a spectrum of histological characteristics ranging from simple steatosis to steatohepatitis, 
fibrosis and cirrhosis and can be characterized into to two major phenotypes: 
nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Water 
disinfection byproducts like trihalomethanes can act as crucial risk factors for NAFLD 
progression. Here I have studied the molecular mechanisms of a water disinfection 
byproduct, Bromodichloromethane, in induction of hepatic inflammation and 
fibrogenesis. I found that Bromodichloromethane (BDCM) can induce hepatic 
fibrogenesis and NASH by inducing leptin mediated activation of NADPH oxidase and 
subsequent increase in microRNA21 expression, resulting in augmented hepatic TGFβ 
signaling. I also explored the hepatoprotective effects of a plant derived TLR4 antagonist 
Sparstolonin B (SsnB) and found that it inhibited BDCM induced TLR4-Flottilin co-
localization, decreased microRNA21 expression and reduced the expression of a myriad 
of inflammatory markers in liver when administered in vivo. Similar effects of SsnB were 
also observed in cell culture model of kupffer cells. Anti-fibrotic and anti-proliferative 
mechanisms of SsnB were observed in a BDCM induced mice NASH model and in 
hepatic stellate cell (HSC) culture. Mechanistically, SsnB decreased activation and pro-
fibrogenic proliferation of HSCs. SsnB could inhibit hedgehog signaling pathway, 
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decreased proliferation and induced apoptosis in HSCs. SsnB decreased TGFβ signaling 
by upregulating BAMBI and decreased STAT3 activation in HSCs. SsnB also changed 
the morphology of fibrogenic stellate cells by downregulating focal adhesion adaptor 
protein and stress fibers. Thus, my research unravels novel molecular mechanisms of 
hepatic fibrogenesis in NASH and proposes the use of Sparstolonin B to ameliorate 
hepatic inflammation and fibrosis in NASH. 
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Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver 
disease in the world with the increased prevalence of obesity and metabolic syndrome(1). 
The prevalence of NAFLD is around 30% adult population, 80-90% of obese adults, 30-
50% diabetic patients and around 90% in patients having hyperlipidemia. In children, the 
prevalence of NAFLD is 3-10% rising up to 40-90% in obese children(2). Ranging from 
simple fat deposition or steatosis in the liver to nonalcoholic steatohepatitis (NASH), 
NAFLD involves a continuum of histological characteristics. Not all individuals having 
steatosis develop severe diseases, however, NASH can lead to cirrhosis and end-stage 
liver diseases(3). In the United States, NASH is the second most common liver diseases 
among the adults who are awaiting liver transplant. The mortality of NASH affected 
patients can also increase by cardio-vascular damage. According to the multiple hit 
hypothesis of NASH, steatosis makes the liver vulnerable to secondary hits which are 
responsible for inducing hepatic inflammation, fibrosis and end stage liver diseases (3). 
Increased consumption of high fat diet, excess lipolysis from adipose tissue, decreased fat 
export in VLDL (very low-density lipoprotein) form, augmented de novo lipogenesis, 
reduced free fatty acid β-oxidation- all these factors can lead to hepatic steatosis. Insulin 
resistance plays an important role to aggravate this
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 process by initiating considerable metabolic dysregulation (4). Circulatory cytokines, 
hypoxia and death of adipocytes can trigger inflammation in the steatotic liver. 
Interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), and CC-chemokine ligand-2 
(CCL2) secreted from inflamed adipocytes can regulate insulin resistance, induce 
macrophage infiltration and other pro-inflammatory cascades (5). However, adiponectin 
secreted by adipocytes is an anti-inflammatory adipokine that enhances insulin 
sensitivity, helps in expansion of healthy adipocytes, prevents ectopic lipid deposition 
and regulates hepatic β-oxidation of fatty acids (6). Leptin is another adipokine and it 
maintains homeostatic control of adipose tissue mass (7). NAFLD is associated with 
leptin resistance (8). NASH patients have been found to have higher serum leptin levels 
than controls. Leptin has fibrogenic potential. However, serum adiponectin level 
decreases in NASH patients compared to healthy controls. Leptin has been found to 
augment inflammation, activate hepatic stellate cells, increase TGFβ signaling and induce 
insulin resistance. However, adiponectin decreases hepatic stellate cell proliferation, 
decreases inflammation and fibrogenesis (9). De novo Lipogenesis, Insulin resistance, 
lipotoxicity, mitochondrial dysfunction, Endoplasmic Reticulum stress-all these factors 
can facilitate the transition from simple steatosis to NASH (4). Several environmental 
pollutants can act as secondary mediators and induce injury in steatotic liver. Studies in 
mice, human adults and also children have shown that air pollution can induce insulin 
resistance, increase oxidative stress in obese liver and thus plays a chief role on the 
development of NAFLD (10). Inhaled particulate matter can increase systemic 
inflammation, increase the levels of triglyceride, LDL, VLDL and increased pro-
inflammatory cytokines. In the liver, the particles can induce kupffer cell activation, 
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activate JNK, NF-kB, TLR4 signaling pathways, affect PPAR activity, alter glucose and 
fat metabolism etc.(11). Heavy metal containing particulate matters, when hit the liver, 
can affect lipid metabolism and trigger oxidative stress in the liver (12). Dioxin 
contaminants which are generated during incineration of domestic and industrial wastes, 
can escape in the nature from the incinerators. They are known to induce steatohepatitis 
by down regulating hepatic carboxylesterase 3 (CES3), activating signal transducer and 
activator of transcription 3 (STAT3), transforming growth factor (TGFβ), IL-6, and 
SMAD signaling pathways (13). Liver plays an important role in detoxification of drugs, 
hormones and environmental pollutants. Industrial chemicals, drinking water byproducts 
like trihalomethanes (THMs) are known to be associated with fatty liver disease and 
hepatic injury. Trihalomethanes are short lived halogenated compounds which are formed 
when disinfectants come in contact with natural organic matter. Bromodichloromethane 
(BDCM), trichloromethane (TCM), dibromochloromethane (DBCM) and 
tribromomethane (TBM) are four THMs found in disinfectant treated water and humans 
are exposed to them through ingestion, inhalation and dermal as THMs may enter human 
body through drinking water, showering, swimming, mopping etc. (14). Several 
experimental and epidemiological studies found the association between trihalomethane 
expore with hepatic injury and disbetes mellitus (14). A current cross-sectional study 
utilizing the U.S. NHANES 1999–2006 data has reported that ALT levels (a marker of 
liver injury) was increased in individuals exposed to higher than the median blood 
brominated trihalomethane levels (15). As liver metabolizes the xenobiotic compounds in 
circulation and process the absorbed contents from the gastrointestinal tract, it is the 
primary target organ for human THM exposure which was supported by some previous 
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studies from our lab where low acute exposure of bromodichloromethane (BDCM) in diet 
induced obese mice was found to generate free radicals followed by CYP2E1 mediated 
metabolism resulting in oxidative stress, protein free radical formation and lipid 
peroxidation. BDCM induced oxidative stress also promotes glucose transport, glycolysis 
and gluconeogenesis resulting in dysfunctional lipid metabolism and NASH development 
(16-18). Increased hepatic leptin followed by BDCM exposure in obese mice augmented 
hepatic inflammation, kupffer cell activation and hepatic fibrogenesis resulting in NASH 
progression (16, 19). In the first chapter of my thesis, I explored the pro-fibrogenic role 
of BDCM where BDCM induced NADPH oxidase induced mir21 expression in liver and 
increased TGFβ signaling (20). 
Alteration of the gut microbiota and induced permeability of intestinal barrier can 
also trigger hepatic inflammation and metabolic disorders. Endotoxins like 
Lipopolysaccharide (LPS) augments NASH pathogenesis as observed in many studies 
(21, 22). Stimuli by pathogen associated molecular patterns (PAMPS) are responded by 
innate immune response through toll like receptors (TLRs) and NOD-like receptors 
(NLRs). Apart from inflammation though gut leaching, tissue injury and cell death can 
also induce sterile inflammation and activate TLR4 in liver giving rise to NASH related 
liver injury (3). TLR family of receptors can get activated by damage associated 
molecular patterns (DAMPs) released during oxidative stress induced tissue injury (23). 
Interestingly, BDCM induced NADPH oxidase activation can produce peroxinitrite 
which can induce TLR4 recruitment in the lipid rafts, augment TLR4 signaling, increase 
IL-1β production, sinusoidal injury and kupffer cell activation resulting in NASH (24). 
TLR4 activation can lead to increased IKK and JNK activation, increased NFkB 
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translocation into nucleus etc., which leads to inflammation, fibrosis, insulin resistance 
and other metabolic dysregulation during NASH (25-27).  
Our collaborators have characterized and published studies of a TLR4 antagonist, 
Sparstolonin B (SsnB) derived from a Chinese herb, Sparganium stoloniferum, an herb 
historically used in traditional Chinese herbal medicine as an anti-inflammatory, anti-
tumor agent. As identified by NMR and X-ray crystallography, SsnB is a polyphenol 
with structural similarities to isocoumarins and xanthone-all these compounds are known 
for anti-inflammatory, anti-oxidant and anti-tumor properties (28). SsnB has been shown 
to disrupt TLR4 and TLR2 dependent downstream signaling pathways, including NfkB 
and MAPK (28). We are the first group to test the therapeutic effect of this compound in 
NASH. In the second chapter of my thesis I report that SsnB attenuates of liver 
inflammation in early NASH through inhibiting TLR4 migration into the lipid rafts (19). 
As chronic inflammation and TLR4 activation leads to increased stellate cell activation 
and excessive extracellular matrix deposition in NASH liver (27), we aim to use SsnB to 
reduce NASH related liver fibrosis by abrogating the TLR4 signaling. The third and 
fourth chapters of this thesis examine the molecular mechanism of SsnB in attenuation of 
stellate cell (HSC) activation, proliferation and fibrosis. It is important to target hepatic 
stellate cell to attenuate liver fibrosis and cirrhosis. These cells are also involved in liver 
cancer and acute liver injury. We found that SsnB significantly decreased stellate cell 
activation and proliferation by downregulating pro-fibrogenic cell signaling pathways. 
We have also observed that SsnB inhibits the focal adhesion adaptor protein, causes loss 
of stress fibers and induces apoptosis in HSCs. Thus, my research provides a novel (i) 
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Abstract: 
Hepatic fibrosis in NASH is the common pathophysiologic process resulting from 
chronic liver inflammation and oxidative stress. Though significant research has been 
carried out on the role of leptin induced NADPH oxidase in fibrogenesis, the molecular 
mechanisms that connect leptin-NADPH oxidase axis in upregulation of TGF-β signaling 
has been unclear. We aimed to investigate the role of leptin mediated upregulation of 
NADPH oxidase and its subsequent induction of miR21 in fibrogenesis. Human NASH 
livers and a high fat (60% kCal) diet fed chronic mouse model where hepatotoxin 
bromodichloromethane was used to induce NASH, were used for this study. To prove the 
role of Leptin-NADPH oxidase-miR21 axis, mouse deficient in genes for leptin, p47phox 
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and miR21 were used. Results showed that wild type mice and human livers with NASH 
had increased oxidative stress, increased p47phox expression, augmented NF-kB 
activation and increased miR21 levels. These mice and human livers showed increased 
TGF-β, SMAD2/3-SMAD4 colocalizations in the nucleus, increased Col1α and α-SMA 
expression with a concomitant decrease in protein levels of SMAD7. Mice that were 
deficient in leptin or p47phox had decreased activated NF-kB and miR21 levels 
suggesting the role of leptin and NADPH oxidase in inducing NF-kB mediated miR21 
expression. Further miR21 KO mice had decreased co-localization events of SMAD2/3-
SMAD4 in the nucleus, increased SMAD7 levels and decreased fibrogenesis. Taken 
together the studies show the novel role of leptin-NADPH oxidase induction of miR21 as 
a key regulator of TGF-β signaling and fibrogenesis in experimental and human NASH. 
2.1 INTRODUCTION 
Pathogenesis of NASH is not clearly understood and perceived to comprise of an 
inflammatory phase of high circulatory leptin, increased oxidative stress, elevated 
inflammatory cytokines resulting in hepatocellular injury and subsequent progression into 
fibrosis (29). Most NASH pathophysiology is accompanied by a late stage fibrosis (30-
32). Hepatic fibrosis in NASH most likely occurs from chronic liver inflammation 
associated with rise in pro inflammatory cytokines and oxidative stress (33). Fibrosis is 
closely linked to accumulation of extracellular matrix (ECM) proteins, mainly type I 
collagen, which also can occur in many chronic liver diseases(33). The accumulation of 
ECM proteins distorts the hepatic architecture by forming a fibrous scar and the 
subsequent development of nodules of regenerating hepatocytes can lead to condition 
known as cirrhosis (34). Since NASH might arise almost always from a preexisting 
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condition of obesity, type 2 diabetes, insulin resistance, the higher circulatory levels of 
adipose tissue cytokines leptin and TNF-α has been predicted to play a significant role in 
hepatic fibrogenesis (35). We and others have shown in rodent models of NASH that 
higher leptin is closely associated with fibrosis in NASH (36-38).  
Leptin, a product of the ob gene, is synthesized in the liver and the adipose tissue 
(39). We have shown that mice fed with a high fat diet and challenged with low doses of 
hepatotoxins cause increase in both hepatic and circulatory levels of leptin (17, 40). An 
early study by Honda H et al. showed that leptin deficiency is responsible for resistance 
to thioacetamide induced fibrogenesis whereas subsequent studies have highlighted the 
role of leptin in stellate cell activation, leptin induced TGF-β production via Kupffer cells 
and leptin signaling induced collagen production and extracellular matrix formation (40-
45).  
Although leptin has been found to play a distinct role in the stellate cell activation 
and TGF-β production, molecular mechanisms involving reactive oxygen species, 
especially the role of NADPH oxidase were revealed  recently (33). NADPH oxidase , 
both the phagocytic and non-phagocytic isoforms has been detected in the liver cell types 
(46). Hepatic stellate cells has been found to express the NADPH oxidase isoform 2 
(NOX2) and deletion of one of its cytosolic subunits have resulted in decreased fibrosis 
in rodent models of NASH (33). Further published reports from our laboratory have 
identified the role of peroxynitrite, a highly reactive nitroso species formed by superoxide 
and nitric oxide in NASH (40). We further showed that NADPH oxidase was crucial for 
peroxynitrite formation that was again dependent on leptin (40). 
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 It is also critical that high circulatory levels of leptin accompanied by leptin 
resistance are common in patients with liver fibrosis (47). Quiescent hepatic stellate cells 
in humans express very low levels of p47phox, a regulatory subunit of NADPH oxidase 
but they are highly activated in culture activated stellate cells isolated from patients with 
liver fibrosis (48).  
Although significant research has been carried out on the leptin induced NADPH 
oxidase in fibrogenesis, the molecular mechanisms that connect leptin-NADPH oxidase 
axis in upregulation of TGF-β signaling has been unclear. Reactive oxygen species 
production by NADPH oxidase, primarily in the form of superoxide or hydrogen 
peroxide has been shown to induce nuclear translocation of NF-kB (49). Our unpublished 
reports indicate that NF-kB activation led to epigenetic modulations in the form of 
upregulation of micro RNA 21 in NASH. Micro RNA 21 (miR21) is a small noncoding 
RNA that has been found to have a distinct role in inflammation and their regulatory 
functions in NASH pathophysiology are slowly emerging (50, 51).  
miR21 upon induction target several proteins either by binding entirely to the 
complementary sequence of mRNA of the target protein resulting in a nonfunctional 
mRNA or binding partially to cause a translational defect (52). Regulatory protein 
SMAD7 which plays an important role in TGF-β signaling, is a target of miR21 and has 
been shown to reverse the regulatory effect of this protein (53, 54). Importantly, TGF-β 
signaling is crucial to the fibrogenesis in NASH and has been shown conclusively in 
many studies (55, 56). 
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In this study, we test the hypothesis that high circulatory leptin induced NADPH 
oxidase-NF-kB activation causes miR21 mediated SMAD 7 inhibition resulting in 
increased TGF-β signaling. The resultant inhibition of SMAD 7 a regulatory SMAD 
leads to uninterrupted TGF-β function causing fibrogenesis in NASH. The results 
obtained via the use of a rodent model of NASH, human tissues and transgenic mice 
lacking leptin, p47phox and miR21 show that leptin induced NADPH oxidase causes 
activation of NF-kB and subsequent upregulation of miR21. Lack of miR21 led to 
significantly less fibrogenesis, TGF-β production, and downstream signaling of TGF-β 
pathway. 
2.2 MATERIALS AND METHODS 
Obese mice:  Adult male, pathogen-free, 6 weeks old mice with C57BL/6J background 
(Jackson Laboratories, Bar Harbor, Maine) were used as model for diet induced obesity. 
The animals were fed with high-fat diet (60% kcal) from 6 weeks to 16 weeks to develop 
diet induced obesity (DIO). After completion of 16 weeks, all experiments were 
conducted. Mice which contained disrupted ob gene (leptin) (B6. V-Lepob/J) (Jackson 
Laboratories) (ob/ob), another group of leptin knockout mice (ob/ob) treated with leptin 
(leptin supplemented group, ob/ob + Leptin), disrupted p47 phox gene(B6.129S2-
Ncf1tm1shl N14) (Taconic, Cranbury, NJ) (p47 phox KO) and mice with disrupted 
microRNA21 gene (B6;129S6-Mir21atm1Yoli/J) (miR21 KO) were fed with a high-fat 
diet and treated identically to DIO mice. The mice were housed one per cage in a 
temperature-controlled room at 23-24°C with a 12-h/12-h light/dark cycle with libitum 
access to food and water. All animals had been treated in strict accordance with the NIH 
guideline for Humane Care and Use of Laboratory Animals and local IACUC standards. 
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All experiments were approved by the institutional review board at NIEHS, Duke 
University and the University of South Carolina. 
Induction of liver injury in obese mice (Toxin Model): Bromodichloromethane 
(BDCM) (2.0m mole/kg, diluted in corn oil) was administered through intraperitoneal 
injection in 16 weeks old DIO mice (n=6). Liver tissues were collected and pooled after 
24 hour exposure of BDCM (DIO+BDCM (24h)) and after 48 hour exposure of BDCM 
(DIO+BDCM (48h)). The other group of DIO mice was administered two doses of 
BDCM (1.0 mmole/kg, diluted in corn oil)/ week for one week (DIO+BDCM (1w)) and 
for four weeks (DIO+BDCM (4w))(n=4). 16 weeks old high fat diet fed DIO mice, 
administered with 100ng GdCl3   per day via intraperitoneal route for 4 weeks were also 
administered with BDCM (1.0mmole/kg, diluted in corn oil) through the intraperitoneal 
route (GdCl3 treated). 16 weeks old high fat diet fed gene specific knockout mice (ob/ob, 
p47 phox KO, miR21 KO) mice were administered with BDCM (1.0mmole/kg, diluted in 
corn oil) through the intraperitoneal route (n=3). DIO mice was treated with corn oil 
(diluent of BDCM) to use as control. After completion of the treatments, all mice were 
sacrificed for liver tissue for the further experiments. The tissues were pooled and used 
for the study. 
Human tissues: Human liver tissues both from NASH and normal individuals were 
obtained from NIH repository at University of Minnesota and University of Pittsburg. 
Each experiment was carried out using 3 experimental group and 3 control samples. 
Histopathology: Liver sections were collected from each animal and fixed in 10% 
neutral buffered formalin. These formalin-fixed, paraffin embedded tissues were cut in 
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5μm thick sections. These sections were deparaffinized using standard protocol and 
stained with Picro-Sirius red. Picro-Sirius red staining of liver sections was done by using 
Nova ultra sirius red stain kit following manufacturer’s protocol (IHC world, Woodstock, 
MD) and they were observed using 20x objectives under the light microscope.  
Immunohistochemistry: Formalin-fixed, paraffin embedded tissues were cut in 5μm 
thick sections. Each section was subjected to deparaffinization using standard protocol. 
To describe briefly, these sections were washed with two changes of 100% xylene twice 
for 3 min followed by xylene: ethanol (1:1) for 3 min, and rehydrated through a series of 
ethanol (twice with 100%, 95%, 70%, and 50%), twice with distilled water. The sections 
were finally rinsed twice with PBS. Epitope retrieval of the deparaffinized sections was 
carried out using epitope retrieval solution and steamer (IHC-World, Woodstock, MD) by 
following the manufacturer’s protocol. The primary antibodies 1) anti-3 nitrotyrosine, 2) 
anti-TGFβ, 3) anti-CTGF, 4) anti-EDAFN, 5) anti-α-SMA, 6) anti-Col 1α1 were 
purchased from Abcam (Cambridge, MA) and used in recommended dilutions. Species 
specific biotinylated conjugated secondary antibody and streptavidin conjugated with 
HRP were used from Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) to 
perform antigen-specific immunohistochemistry following manufacturer’s protocols. 3, 
3’ Diaminobenzidine (Sigma-Aldrich, St.Louis, MO) was used as a chromogenic 
substrate. Tissue sections were counter-stained by Mayer’s hematoxylin (Sigma-Aldrich). 
Phosphate buffer saline was used for washing thrice between the steps. Sections were 
mounted in Simpo mount (GBI Laboratories, Mukilteo, WA) and observed under a 20x 




Immuno-fluorescence dual-labelling microscopy: Formalin-fixed, paraffin embedded 
tissues were cut in 5μm thick sections. Each section was subjected to deparaffinization 
using standard protocol. Epitope retrieval of the deparaffinized sections was carried out 
using epitope retrieval solution and steamer (IHC-World, Woodstock, MD) by following 
the manufacturer’s protocol. The primary antibodies anti-SMAD2/3, anti-SMAD4, and 
anti-gp-91phox, anti-p47phox (purchased from Cell Signaling Technology, MA and 
Santa Cruz biotechnology, Inc. Santa Cruz, CA) and used at recommended dilutions. 
Species-specific anti-IgG secondary antibodies conjugated with Alexa Fluor 488, Alexa 
Fluor633 (Invitrogen, California, USA) were used together against anti-SMAD4 and anti-
SMAD2/3 respectively. Alexa Fluor 488 and Alexa Fluor 568 were used together against 
anti-p47phox and anti-gp91phox respectively. The sections were mounted in a ProLong 
gold antifade reagent with DAPI (Life technologies, EU, OR). Images were taken under 
20x/60x oil objectives using Olympus BX51 microscope. 
Quantitative Real-Time Polymerase Chain Reaction Analysis (qRT-PCR): Real-time 
reverse transcription-polymerase chain reaction was done to measure gene expression 
(mRNA) levels in the liver tissue samples. Total RNA was isolated from each liver tissue 
by homogenization in TRIzol reagent (Life Technologies, Carlsbad, CA) according to 
manufacturer’s instruction and was purified by using RNeasy mini kit columns (Qiagen, 
Valencia, CA). iScript cDNA synthesis kit (Bio-rad, Hercules, CA) was used to convert 
1µg of purified RNA to cDNA following the manufacturer's standard protocol. qRTPCR 
was performed with the gene specific primers by using SsoAdvanced universal SYBR 
Green supermix (Bio-Rad, Hercules, CA) and CFX96 thermal cycler (Bio-Rad, Hercules, 
CA). Threshold Cycle (Ct) values for selected genes were normalized against 18S 
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(internal control) values in same sample. For each gene and each tissue sample, each 
reaction was carried out in triplicates. Liver sample from DIO mice was used as control 
to compare with all other liver samples in the toxin model of NASH. The relative fold 
change was calculated by the 2-∆∆Ct method. The primers used for Real time PCR in 
5’to 3’ orientation are Human p47phox (Forward: GTACCCAGCCAGCACTATG, 
Reverse: CCTGGCTTTGCTTTCATCTG) and Mouse p47phox (Forward: 
GGTCGACCATCCGCAACGCA, Reverse: TGTGCCATCCGTGCTCAGCG). 
miR21 expression levels in liver tissues: Total miRNA was isolated from liver tissue by 
homogenization in Qiazol reagent (Qiagen, Valencia, CA) following the manufacturer’s 
instructions. The purification was done by using miRNeasy mini kit columns (Qiagen, 
Valencia, CA). 1000ng of purified miRNA was converted to cDNA using miScript 
cDNA synthesis kit (Qiagen, Valencia, CA) following the manufacturer's protocol. 
qRTPCR was performed with microRNA specific primers (Qiagen, Valencia, CA) using 
miScript SYBR Green PCR master mix (Qiagen, Valencia, CA) and CFX96 thermal 
cycler (Bio-rad, Hercules, CA). Threshold Cycle (Ct) values for the selected gene was 
normalized against RNU6-2 (internal miR expression control) values in the same sample. 
Western Blotting: 30 mg of each liver tissue was homogenized in 500 µl of RIPA buffer 
(Sigma Aldrich) in the presence of phosphatase and protease inhibitor (Pierce, Rockford, 
IL) by using dounce homogenizer. After centrifuging the homogenate, the supernatant 
was collected for further experiments. 30 µg of protein from each sample was loaded on 
4–12% bis-tris gradient gel (Invitrogen, California, USA) for SDS PAGE. By using 
precut nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories Inc., California, 
USA) and Trans – Blot Turbo transfer system (Bio-Rad), proteins were transferred to 
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nitrocellulose membrane. Blots were blocked with 5% non-fat milk solution. Primary 
antibody against SMAD7 and β-actin (purchased from Abcam) were used at 
recommended dilutions and incubated overnight at 4ºC. Species specific secondary 
antibody conjugated with HRP was used. Pierce ECL Western Blotting substrate 
(Thermo Fisher Scientific Inc., Rockford, IL) was used. The blot was developed by using 
BioMax MS Films and cassettes (with intensifying screen, Kodak). Densitometry 
analysis of the images was done using Lab Image 2006 Professional 1D gel analysis 
software from KAPLEAN Bioimaging Solutions (Liepzig, Germany). 
NF-kB transcription factor binding assay: Nuclear fraction of each liver samples were 
isolated by using NF-kB assay kit and following manufacturer’s standard protocol (Five 
photon Biochemicals). DNA binding activity of the transcription factor NF-kB present in 
those nuclear extracts was detected using enzyme-linked immunosorbent assay (ELISA) 
method (Abcam's NF-kB p65 Transcription Factor Assay Kit) following manufacturer’s 
standard protocol.  
Statistical Analyses: In vivo experiments were repeated two-three times with an average 
of 3 mice per group with other in vivo experiments having 4-6 mice/group (n=3/4/6 
wherever applicable; data from each group of mice was pooled). The statistical analysis 
of data was done by analysis of variance (ANOVA) followed by Bonferroni post-hoc 
correction for performing intergroup comparisons. Quantitative data from Western blots, 
depicted by the relative intensity of the bands were analyzed by performing student’s t 





Leptin induces NADPH oxidase subunit p47phox and membrane association with 
gp91phox in NASH of both mice and humans. We have shown previously that leptin 
induces p47phox in early steatohepatitis leading to the formation of peroxynitrite and 
corresponding inflammation and Kupffer cell activation (57). To prove the role of leptin 
in induction of p47phox in fibrogenesis of NASH, experiments were performed in both 
mice model of NASH and human tissue samples from NASH patients. Results showed 
that DIO+BDCM group that shows typical NASH lesions had a 1.6-fold increase in 
p47phox mRNA expression as compared to DIO group alone (P<0.05) (Figure 2.1 A). 
Leptin knockout (ob/ob) mice showed a significant decrease in p47phox expression as 
compared to DIO+BDCM group (P<0.05), while leptin supplementation in leptin 
knockout (ob/ob+Leptin) mice resulted in a significant upregulation of p47phox mRNA 
as compared to only leptin knockout (ob/ob) mice (P<0.01). Human NASH (Hu NASH) 
tissues showed a significant increase p47phox mRNA expression as compared to controls 
(Hu CTRL) (P<0.05) (Figure 2.1 B). p47phox subunit of NADPH oxidase requires its 
association with its membrane counterpart gp91phox for activation of this enzyme. We 
studied the membrane association of these two subunits by immunofluorescence 
microscopy in both mice and human tissue samples. Results were analyzed based on the 
number of colocalization/overlay events (shown by yellow) per 300 cells counted (Figure 
2.1 C and D). Results showed that DIO+BDCM group had a significant increase in the 
colocalization events as compared to DIO group only (P<0.01) (Figure 2.1 C and D). 
Leptin knockout (ob/ob) mice had a significant decrease in the number of colocalization 
events as compared to DIO+BDCM group (P<0.01). Leptin supplemented Leptin 
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Knockout mice (ob/ob+Leptin) had a significant increase in the colocalization events as 
compared to leptin knockout (ob/ob) mice (P<0.05) (Figure 2.1 C and D). Human NASH 
samples showed a significant increase in the p47phox/gp91phox colocalization as 
compared to human controls (Figure 2.1 C and D) (P<0.05). The above results suggest 
that leptin induced p47phox expression in NASH and aided in the membrane association 
of p47phox and gp91phox that assumes significance in causing oxidative stress in NASH. 
Leptin induced NADPH oxidase activation causes peroxynitrite mediated oxidative 
stress in both NASH of mice and humans. We have previously shown that 
peroxynitrite mediated oxidative stress plays a crucial role in activating Kupffer cells in 
early steatohepatitic lesions in NASH (57). To prove that leptin-induced activation of 
NADPH oxidase in causing oxidative stress through peroxynitrite formation, experiments 
were performed in vivo to estimate 3-nytrotyrosine (3 N-Tyr) immunoreactivity in these 
tissues (Figure 2.2). Results showed that 3-nitrotyrosine immunoreactivity was 
significantly increased in DIO+BDCM group as compared to DIO group (P<0.05) 
(Figure 2.2 A and B). Leptin knockout (ob/ob) mice had a significant decrease in 3-
nitrotyrosine immunoreactivity as compared to DIO+BDCM group (P<0.05). Leptin 
supplemented leptin knockout (ob/ob+Leptin) mice showed a significant increase in the 
3-nitrotyrosine immunoreactivity as compared to leptin knockout (ob/ob) mice (P<0.05). 
Human NASH samples (n=3) showed a significant increase in 3-nitrotyrosine 
immunoreactivity as compared to human controls as shown by morphometry analysis of 
the slides (P<0.05) (Figure 2.2 B). All morphometric analysis of the stained liver sections 
was expressed as percentage area of immunoreactivity (Figure 2.2 B). The results 
suggested that leptin was significantly associated with increase in 3-nitrotyrosine 
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immunoreactivity and peroxynitrite might be a prominent player in causing oxidative 
stress. 
Leptin induced NADPH oxidase activation mediates NF-kB translocation to the 
nuclei and upregulation of miR21. NADPH oxidase mediated oxidative stress has been 
shown to induce NF-kB translocation (49). NF-kB translocation and its binding to miR21 
promoter are crucial for many inflammatory events in disease progression (58). To prove 
that leptin, through its activation of NADPH oxidase in vivo causes NF-kB translocation 
and binding to DNA, we performed experiments with liver tissue of both mice and 
humans. Results showed that NF-kB activation and DNA binding was significantly 
increased in DIO+BDCM group as compared to DIO group only (P<0.05) (Figure 2.3 A). 
Leptin knockout (ob/ob) mice showed a significant decrease in the NF-kB activation and 
binding as compared to DIO+BDCM group (P<0.05). p47phox knockout mice which 
cannot participate in NADPH oxidase mediated oxidative stress also showed a significant 
decrease in NF-kB activation and binding to DNA as compared to DIO+BDCM group 
(P<0.05) (Figure 2.3 A). Human NASH samples from liver showed a significant increase 
in NF-kB activation and binding to DNA as compared to corresponding control tissues 
(P<0.01) (Figure 2.3 B). DIO+BDCM group had a significant increase in miR21 levels (4 
fold) as compared to DIO group (P<0.01) (Figure 2.3 C). Leptin knockout (ob/ob) or 
p47phox knockout mice had a significant decrease in miR21 levels as compared to 
DIO+BDCM group (P<0.01) (Figure 2.3 C). However Leptin supplementation to leptin 
knockout (ob/ob+Leptin) mice had a significant increase in miR21 levels as compared to 
leptin knockout (ob/ob) mice and had comparable levels of miR21 with DIO+BDCM 
group (P<0.01) (Figure 2.3 C). Human liver samples that had NASH etiology, had 
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significantly higher miR21 levels (4.5 fold) as compared to human control tissues 
(P<0.01) (Figure 2.3 D). The above results suggested that leptin mediated NADPH 
oxidase activation was significantly associated with increased miR21 levels in NASH. 
The results assume significance since miR21 mediated repression of its target proteins 
can play a major role in disease pathology. 
Leptin mediated NADPH oxidase activation and its corresponding induction of 
miR21 represses regulatory SMAD protein in both mice and human NASH. miR21 
has been found to repress many functional proteins in disease pathology (59). SMAD7, a 
regulatory protein in the TGF-β signaling cascade has been shown to be a target for 
miR21 (54). We studied the role of Leptin-NADPH oxidase axis in mediating miR21-
induced SMAD7 repression. Results showed that protein levels of SMAD7 were 
significantly elevated during the initial phases of NASH development (DIO+BDCM, 
48h) as compared to DIO group. The protein levels of SMAD7 decreased significantly at 
1w and at the termination of the study (4w) that showed full-blown NASH symptoms and 
correlated well with fibrotic lesions (P<0.05) (Figure 2.4.A and C). miR21 knockout 
mice showed a significant increase in SMAD7 protein expression as compared to 
DIO+BDCM group at 4 weeks (P<0.01) (Figure 2.4.B and D). Leptin knockout (ob/ob) 
mice or p47phox knockout mice or DIO+BDCM mice that were depleted with 
macrophage toxin GdCl3 did not show any significant protein levels of Smad7 (Figure 
2.4.B and D). This is not surprising since these mice did not have oxidative stress and 
there was no induction of SMAD7 in the initial phases (data not shown). Human NASH 
tissues showed a significant decrease in SMAD7 protein levels as analyzed by western 
blot as compared to corresponding controls (P<0.01) (Figure 2.4.B and D). The results 
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suggested that the increased miR21 in mice and human NASH is strongly associated with 
decreased SMAD7 protein. The results assume significance since SMAD7 plays a crucial 
role in regulating and inhibiting TGF-β signaling, crucial for fibrogenesis in NASH. 
Leptin mediated NADPH oxidase activation and corresponding induction of miR21 
regulate TGF-β levels in mice and human NASH. TGF-β  has been shown to be key 
for NASH fibrogenesis (60). To prove the role of leptin mediated NADPH oxidase 
induction of miR21 in regulating TGF-β levels in NASH, experiments were performed 
with liver slices of mice and human NASH tissues and assessing the immunoreactivity by 
using immunohistochemistry. Results showed that DIO+BDCM group had a significantly 
increased level of TGF-β as compared to DIO group (P<0.01) (Figure 2.5A and B). 
Leptin knockout (ob/ob), p47phox knockout and miR21 knockout mice had a significant 
decrease in TGF-β immunoreactivity as compared to DIO+BDCM group (P<0.01) 
(Figure 2.5A and B). Leptin supplementation to leptin knockout (ob/ob+Leptin) mice 
showed a significant increase in TGF-β immunoreactivity as compared to leptin knockout 
(ob/ob) mice alone (P<0.05) (Figure 2.5A and B). Human NASH liver slices showed a 
significant increase in TGF-β  immunoreactivity as compared to control tissues as shown 
by percentage area covered by the immunoreactive staining (morphometric analysis) 
(P<0.05) (Figure 2.5A and B). The results suggested that leptin mediated NADPH 
oxidase activation and miR21 induction plays a crucial role in TGF-β levels in the livers 
of NASH. 
Leptin mediated NADPH oxidase activation and corresponding induction of miR21 
in NASH are crucial for regulation of SMAD2/3-SMAD4 assembly in the nucleus, a 
key event in TGF-β signaling pathway. TGF-β signaling through SMAD2/3 is crucial 
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for collagen deposition and fibrogenesis (61-63). It has been shown previously that 
SMAD2/3 binds with SMAD4 and translocate to the nucleus. The nuclear colocalization 
of the SMAD2/3-SMAD4 heterodimer complex is key event in TGF-β functional 
pathway. TGF-β induces heteromeric complexes of SMADs 2, 3 and 4, and their 
concomitant translocation to the nucleus, which is required for efficient TGF-β signal 
transduction (62). To study the role of leptin mediated NADPH oxidase activation and 
miR21 induction in TGF-β signal transduction pathway, experiments were performed 
using liver tissue slices. Immunoreactivity to SMAD2/3, SMAD4 and their nuclear 
colocalizations were assessed by immunofluorescence microscopy. Results showed that 
the number of colocalization events in the nucleus were significantly higher in 
DIO+BDCM group as compared to DIO group (P<0.01) (Figure. 2.6A and C). The 
colocalization events in the leptin knockout (ob/ob), p47phox knockout and miR21 
knockout mice were significantly decreased as compared to DIO+BDCM group (P<0.01 
and P<0.05). Leptin supplementation to leptin knockout (ob/ob+ Leptin) mice 
significantly increased the number of nuclear colocalization events as compared to leptin 
knockout (ob/ob) mice alone (P<0.05). Human NASH samples showed significant 
increase in SMAD2/3, SMAD7 nuclear colocalizations as compared to Human liver 
controls (P<0.05) (Figure. 2.6A and C). The results were analyzed based on the number 
of nuclear colocalizations per 300 cells (Figure. 2.6C). 60X oil micrographs of 
DIO+BDCM group in the mouse model and Human NASH liver are shown in 
Figure.2.6B. The results show that increased TGF-β induced signaling through SMAD2/3 
and SMAD 4 is regulated by leptin mediated NADPH oxidase and its subsequent 
upregulation of miR21. 
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Leptin mediated NADPH oxidase activation and subsequent miR21 induction 
regulate the levels of TGF-β signaling proteins Connective Tissue Growth factor 
(CTGF) and EDA-Fibronectin in mice model of NASH and human NASH livers. In 
fibrotic liver, connective tissue growth factor (CTGF) is constantly expressed in activated 
hepatic stellate cells (HSCs) and acts downstream of TGF-β to modulate extracellular 
matrix production (64). On the other hand fibronectin (FN) is a major component of the 
extracellular matrix and occurs in two main forms: plasma and cellular FN. The latter 
includes the alternatively spliced domain A (EDA) (65). EDA-Fibronectin has been 
shown to participate in TGF-β mediated fibroblast differentiation and fibrogenesis (66). 
To prove the role of leptin mediated NADPH oxidase activation and subsequent 
induction of miR21 in TGF-β signaling, immunohistochemical analysis of the mice liver 
and human liver tissues were performed. Results showed that there was a significant 
increase in the immunoreactivity of CTGF and EDA-Fibronectin (EDAFN) in 
DIO+BDCM group as compared to DIO group (P<0.01and P<0.05) (Figure.2 7A ii and B 
ii) (Fig.2 7C and D for morphometric analysis). On the other hand leptin knockout 
(ob/ob), p47phox knockout and miR21 knockout mice had a significant decrease in the 
CTGF and EDA Fibronectin levels as compared to DIO+BDCM group (Figure.2 7A iii, v 
and vi) (2.7B iii, v and vi) (Figure.2.7C and D for morphometric analysis) (P<0.05). 
Leptin supplementation in leptin knockout (ob/ob+Leptin) mice showed a significant 
increase in the levels of immunoreactivity of both these crucial proteins (P<0.05) 
(Figure.2 7A iv and 2.7B iv) (Figure.2 7C and D for morphometric analysis). Human 
NASH livers had a significant increase in the immunoreactivity of CTGF and EDA-
fibronectin as compared to control livers (P<0.05) (Figure.2 7A viii and B viii) 
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(Figure.2.7C and 2.7D for morphometric analysis). The above results show that Leptin 
mediated NADPH oxidase activation and subsequent miR21 inhibition of SMAD7 is 
closely associated with increased TGF-β signaling resulting in higher CTGF and EDA-
fibronectin levels in NASH. 
Leptin mediated NADPH oxidase activation and miR21 induction cause stellate cell 
activation and collagen deposition in NASH. Stellate cell activation is a key event for 
NASH progression (16). α-SMA is a biomarker for stellate cell activation (67). 
Importantly, increased fibrogenesis and TGF-β signaling results in higher collagen 1α1 
level in tissues. To show the role of leptin mediated NADPH oxidase in stellate cell 
activation and fibrogenesis, immunohistochemical analyses of mice and human liver 
tissues were performed. Results showed that immunoreactivity to α-SMA and Col1α 
were significantly high in DIO+BDCM group as compared to DIO group (P<0.01) 
(Figure 2.8A ii and 2.8B ii) (morphometric analysis Figure. 2.8C and 2.8D). Leptin 
knockout (ob/ob), p47phox knockout and miR21 knockout mice had significantly 
decreased immunoreactivity of α-SMA and Col1α as compared to DIO+BDCM group 
(P<0.01) (Figure. 2.8A iii, v and vi; 2.8B iii, v and vi) (morphometric analysis 
Figure.2.8C and 2.8D). Leptin supplementation in leptin knockout (ob/ob+Leptin) mice 
showed a significant increase in the levels of both α-SMA and Col1α as compared to 
leptin knockout mice (ob/ob) group alone (P<0.05)(Figure.2.8A iv and 2.8B iv) 
(morphometric analysis Figure. 2.8C and 2.8D). Human NASH liver exhibited a 
significant increase in α-SMA and Col1αas shown by increased immunoreactivity to 
these proteins and morphometric analysis of the tissue staining (P<0.05) (Figure. 2.8A 
viii and 2.8B viii) (morphometric analysis Figure.2.8C and 2.8D). The results suggested 
25 
 
that leptin-mediated NADPH oxidase and the subsequent induction of miR21 regulated 
the stellate cell activation and corresponding collagen deposition in both mice and human 
NASH livers. 
Leptin mediated NADPH oxidase activation and miR21 induction cause fibrogenesis 
in NASH. A. Analysis of picrosirius staining for collagen showed increased reactivity in 
DIO+BDCM group, especially in the periportal regions as compared to DIO group 
(Figure.2.9 A ii). Leptin knockout (ob/ob) or p47phox knockout or miR21 knockout mice 
showed a minimal fibrotic stain as compared to DIO+BDCM group (Figure.2.9 A iii, v 
and vi). Leptin supplementation sharply increased periportal staining of picrosirius red 
(Figure.2.9 A iv) whereas human tissues for NASH showed higher picrosirius red 
staining compared to controls (Figure. 2.9 A viii). To show a correlation between the 
levels of tissue leptin and fibrotic stage, leptin immunoreactivity in mouse liver 
homogenates at 24 h, 48h, 1wk and 4wk as assessed by western blot followed by 
normalizations against β-actin (Figure 2.9 B and C) and by picro sirius red staining 
depicting fibrosis at 24h, 48h, 1w and 4 w in DIO+BDCM group (Figure 2.9 D).. Results 
showed that increased leptin concentrations correlated well with periportal and bridging 
fibrosis at 4 weeks following the toxin exposure in an underlying condition of steatosis 
(NASH model). 
2.4 DISCUSSION 
In this study we report for the first time the role of leptin-mediated NADPH oxidase in 
inducing miR21 in preclinical NASH model as well as in human NASH patients. We also 
show the mechanistic role of miR21 in repressing SMAD7, a crucial regulator of TGF-β 
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signaling, thus modulating fibrogenesis in NASH (Figure.2.10). Significantly, the miR21-
modulation of TGF-β signaling, fibrogenesis and NASH progression were mediated by 
NADPH oxidase in our present study. The study assumes huge clinical significance since 
the role of NADPH oxidase has been shown in fibrogenesis by us and others but the link 
between NADPH oxidase based oxidative stress signaling through posttranscriptional 
epigenetic changes and TGF-β signaling remained largely elusive in vivo. 
An earlier report from our laboratory showed that leptin-mediated NADPH 
oxidase activation activated Kupffer cells largely through the formation of peroxynitrite 
in an early stage of steatohepatitic injury (57). Through the present study, we advanced 
our understanding about the role of leptin-mediated NADPH oxidase based oxidative 
stress in a full blown NASH model and in human NASH livers. The present study used a 
rodent model of NASH that had a hepatotoxin bromodichloromethane (BDCM) as a 
second hit (16). All our investigations were carried out at a time point where NASH 
symptoms were confirmed using clinical indicators. NADPH oxidase subunit p47phox 
induction and subsequent activation were observed in these liver tissues (Figure 2.1. A-
D). The induction and subsequent activation of NADPH oxidase was dependent on the 
presence of leptin since leptin knockout mice (ob/ob) or leptin supplementation (100 ng, 
daily for 4 weeks) in leptin knockout (ob/ob+Leptin) mice had opposite outcomes (Figure 
2.1). Based on our previous reports in the same model, we also established the nature of 
the oxidizing species since we observed significant increase in 3-nitrotyrosine 




Highly reactive oxidizing species has been shown to induce changes in the epigenetic 
foci and cause increases in the expression of non-coding RNAs (68). There are several 
miRNAs that are known to be induced in an inflammatory condition (58, 59). NASH has 
been shown to induce several miRNAs with specific functions targeted towards its 
progression (69-71). miR21 is induced in an inflammatory microenvironment and has 
been shown to be induced in disease pathophysiology following the binding of nuclear 
transcription factor NF-kB to its promoter (58). In the present study we show that NF-kB 
binding activity to the DNA was significantly higher in DIO+BDCM group (NASH 
mouse model) and human NASH livers (Figure 2.3A and B). The activation NF-kB was 
dependent on leptin and NADPH oxidase activation since leptin knockout (ob/ob) mice 
and p47phox knockout mice had significantly lower NF-kB activation (Figure 2.3A). 
Human livers had significant increase in NF-kB activation, an index of oxidative stress 
and inflammatory signaling pathway (Figure 2.3B). Coupled with the NF-kB activation 
our studies also showed that the miR21 levels in the NASH livers were significantly 
elevated (Figure 2.3C and D). The levels of the miR21 were dependent on the NADPH 
oxidase subunit p47phox and leptin. The results correlate well with observations reported 
previously about NF-kB mediated miR21 induction in vitro through a binding of NF-kB 
to miR21 promoter region(72). However the above phenomenon could not be established 
in the in vivo models of NASH due to procedural complications involving transfection in 
primary cells from the NASH mice at this point. Thus it can be justified to assume that 
NF-kB translocation in the NASH livers might bind to miR21 promoter causing its 
induction, apart from the other functions that it is predicted to perform in NASH (Figure 
2.3C and D).  
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A recent review by Noetel et al. describe the current knowledge of the role of miR21 in 
liver fibrosis (51). Inflammatory microenvironment in the NASH livers are predicted to 
promote TGF-β signaling which in turn can stimulate SMAD2/3 phosphorylation and 
their association with SMAD4. Further the above events can up-regulate miR21 which by 
suppressing SMAD7 can further add to the increased TGF-β-mediated profibrogenic 
responses, events that are known in other fibrotic mechanisms in the lung and kidney (54, 
70). We are not aware of any reports that establish a direct role of NADPH oxidase 
activation-induced miR21 in TGF-β signaling and subsequent liver fibrosis. To prove the 
role of miR21-induced SMAD7 repression and SMAD2/3-SMAD4 interactions, we used 
miR21 knockout mice in parallel to p47phox and leptin knockout (ob/ob) mice. Results 
showed that miR21 knockout that show significantly lower inflammation in similarly 
used NASH models (unpublished data), had higher SMAD7 levels when treated 
identically with high fat diet and hepatotoxin challenge as compared to DIO+BDCM 
(Figure. 2.4B and D). Interestingly SMAD7 proteins were significantly decreased in 
human NASH livers as compared to controls (Figure. 2.4B and D). Leptin knockout 
(ob/ob) and p47phox knockout mice had a small increase in protein levels as compared to 
DIO+BDCM at 4 weeks but the reported increase was not statistically significant (Fig. 
4D). This might be due to the genetic makeup of these mice and a very low level of 
inflammation that trigger SMAD 7 protein expression. Also, it’s worth reporting were the 
levels of TGF-β in leptin, p47phox and miR21 knockout mice (Figure.2.5A and B). 
Results showed that these knockout mice had significantly decreased TGF-β levels as 
compared to DIO+BDCM group (Figure.2.5). The results also establish that TGF-β levels 
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are significantly regulated upstream of miR21 induction and leptin, NADPH oxidase and 
miR21 are linked to cause an upregulation of TGF-β.  
TGF-β signaling is crucial for fibrogenesis in NASH. SMAD2/3 association with 
SMAD7 in the nucleus is a crucial event in this process (63). This important mechanistic 
association and its regulation by miR21 have never been shown in liver fibrosis in vivo or 
in human NASH livers. We show by immunofluorescence imaging ex vivo, the 
colocalization of SMAD2/3-SMAD4 in the nuclei of NASH livers (Figure.2.6). Murine 
and Human NASH livers had a significant increase in the number of colocalization 
events as compared to corresponding controls whereas leptin, p47phox and miR21 
knockout mice had significantly less number of colocalization events as compared to 
NASH groups (Figure.2.6C). The results described in this study assume great 
significance since we show that NADPH oxidase through miR21 not only repressed 
SMAD7 as a profibrogenic mechanism but also contributed partly to enhance SMAD2/3-
SMAD4 association in the nucleus, a key event in liver fibrogenesis. The leptin-mediated 
NADPH oxidase induction of miR21 also played a significant role in the downstream 
events of TGF-β signaling pathway by regulating the levels of CTGF and the intracellular 
form of fibronectin (EDA-Fibronectin) (Figure.2.7).  
Finally, we studied the implications of the leptin mediated NADPH oxidase 
activation and subsequent miR21 upregulation in stellate cell activation, collagen levels 
and fibrosis, key events in NASH pathogenesis. Predictably, our results showed a direct 
involvement of leptin-mediated NADPH oxidase and miR21 role in fibrogenesis since 
leptin knockout (ob/ob), p47phox knockout or miR21 knockout mice had significantly 
decreased levels of α-SMA, Col1α and picrosirius red staining as compared to mouse and 
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human NASH models (Figure 2.8 and 2.9). Importantly NASH pathogenesis for proving 
stellate cell activation and fibrosis in both preclinical and clinical settings rely on the 
levels of α-SMA, Col1α and picrosirius red staining. 
In summary, we show that leptin mediated NADPH oxidase upregulated the 
levels of miR21 through NF-kB activation predictively by binding to the miR21 promoter 
in vivo, observations that have been reported previously. The resultant upregulation of 
miR21 caused fibrogenesis in NASH by SMAD2/3-SMAD4 association in the nucleus 
and SMAD7 repression. Our results will help advance the current knowledge about the 
mechanisms of NADPH oxidase mediated fibrogenesis in NASH and will stimulate 
newer studies that can help develop therapeutic approaches for this clinically silent 
disease. 
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Figure 2.1 Leptin induces NADPH oxidase subunit p47phox and membrane association 
with gp91phox. A: qRT-PCR analysis of p47phox mRNA expression of diet-induced 
obesity (DIO), DIO + bromodichloromethane (BDCM), ob/ob, and ob/ob + leptin mice 
samples normalized against DIO. B: qRT-PCR analysis of p47phox mRNA expression of 
human (Hu) nonalcoholic steatohepatitis (NASH) samples normalized against Hu control 
(CTRL). C: immunofluorescence dual-labeling microscopy depicting gp91phox (red)-
p47phox (green) colocalization (yellow) in DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob 
+ leptin (iv), Hu CTRL (v), and Hu NASH (vi) liver samples taken at ×60 (oil) 
magnification. D: morphometric analysis of colocalization events of C, shown in 





Figure 2.2 Leptin-induced NADPH oxidase activation causes peroxynitrite-mediated 
oxidative stress in NASH of both mice and humans. A: 3-nitrotyrosine (3 N-Tyr) 
immunoreactivity as shown by immunohistochemistry in liver slices from the DIO (i), 
DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), Hu CTRL (v), and Hu NASH (vi) 
groups, respectively. Images were taken at ×20 magnification. B: morphometric analysis 




Figure 2.3 Leptin-induced NADPH oxidase activation mediates NF-κB activation and 
upregulation of micro-RNA 21 (miR21). A: normalized % change of NF-κB activation in 
DIO, DIO + BDCM, ob/ob, and p47 phox knockout (KO) samples. B: normalized % 
change of NF-κB activation in Hu CTRL and Hu NASH samples. C: qRT-PCR analysis 
of miR21 expression of DIO, DIO + BDCM, ob/ob, and ob/ob + leptin mice samples 
normalized against DIO. D: qRT-PCR analysis of miR21 expression of Hu NASH 





Figure 2.4 Leptin-mediated NADPH oxidase activation and its corresponding induction 
of miR21 repress regulatory SMAD7 protein both in mice and human NASH. A: Western 
blot analysis of SMAD7 from liver homogenates of DIO, DIO + BDCM 24 h, DIO + 
BDCM 48 h, DIO + BDCM 1 wk (w), and DIO + BDCM 4 w groups, respectively. B: 
Western blot analysis of SMAD7 from liver homogenates of DIO, DIO + BDCM 4 w, 
ob/ob, ob/ob + leptin, p47phox KO, GdCl3-treated sample, miR21 KO, Hu CTRL, and 
Hu NASH groups, respectively. C: immunoreactive band analysis of SMAD7 normalized 
against β-actin. y-Axis depicts the SMAD7/actin ratio from DIO, DIO + BDCM 24 h, 
DIO + BDCM 48 h, DIO + BDCM 1 w, and DIO + BDCM 4 w groups. D: 
immunoreactive band analysis of SMAD7 normalized against β-actin. y-Axis depicts the 
SMAD7/actin ratio from DIO, DIO + BDCM 4 w, ob/ob, ob/ob + leptin, p47phox KO, 
GdCl3-treated sample, miR21 KO, Hu CTRL, and Hu NASH groups. *P < 0.05 and #P < 




Figure 2.5 Leptin-induced NADPH oxidase activation and corresponding induction of 
miR21 regulate transforming growth factor (TGF)-β levels in mice and human NASH. A: 
TGF-β immunoreactivity as shown by immunohistochemistry in liver slices from the 
DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO 
(vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images were taken at ×20 
magnification. B: morphometric analysis of the immunoreactivity of A. *P < 0.05 and #P 




Figure 2.6 Leptin-mediated NADPH oxidase activation and corresponding induction of 
miR21 are crucial for regulation of SMAD2/3-SMAD4 assembly in the nucleus. A: 
immunofluorescence dual labeling depicting SMAD2/3 (red)-SMAD4 (green) 
colocalization (yellow) in the DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), 
p47phox KO (v), miR21 KO (vi), Hu CTRL (vii), and Hu NASH (viii) liver samples, 
taken at ×20 magnification. B: immunofluorescence dual labeling of DIO + BDCM 
(mouse) (i) and Hu NASH (human) (ii) liver samples depicting SMAD2/3 (red)-SMAD4 
(green) colocalization (yellow) taken at ×60 (oil) magnification. C: morphometric 
analysis of colocalization events of A, shown in colocalization events/300-cell unit. *P < 




Figure 2.7 Leptin-mediated NADPH oxidase activation and subsequent induction of 
miR21 regulate TGF-β signaling proteins. Connective tissue growth factor (CTGF) and 
extra domain A-fibronectin (EDAFN) in mice and human NASH. A: CTGF 
immunoreactivity as shown by immunohistochemistry in liver slices from the DIO (i), 
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DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO (vi), Hu 
CTRL (vii), and Hu NASH (viii) groups, respectively. Images were taken at ×20 
magnification. B: EDAFN immunoreactivity as shown by immunohistochemistry in liver 
slices from the DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO 
(v), miR21 KO (vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images 
were taken at ×20 magnification. C: morphometric analysis of the immunoreactivity of A. 
D: morphometric analysis of the immunoreactivity of B. *P < 0.05 and #P < 0.01 are 




Figure 2.8 Leptin-mediated NADPH oxidase activation and miR21 induction cause 
stellate cell activation and collagen deposition in NASH. A: α-smooth muscle actin 
(SMA) immunoreactivity as shown by immunohistochemistry in liver slices from the 
DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO 
(vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images were taken at ×20 
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magnification. B: Col1α1 immunoreactivity as shown by immunohistochemistry in liver 
slices from the DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO 
(v), miR21 KO (vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images 
were taken at ×20 magnification. C: morphometric analysis of the immunoreactivity of A. 
D: morphometric analysis of the immunoreactivity of B. *P < 0.05 and #P < 0.01 are 
considered statistically significant. 
 
Figure 2.9 Leptin-mediated NADPH oxidase activation and miR21 induction cause 
fibrogenesis in NASH. A: picrosirius red (PSR) staining of DIO (i), DIO + BDCM (ii), 
ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO (vi), Hu CTRL (vii), and Hu 
NASH (viii) liver slices. Fibrosis is depicted by red staining. Images were taken at ×20 
magnification. B: leptin immunoreactivity in mouse liver homogenates at 24 h, 48 h, 1 
wk, and 4 wk as assessed by Western blot followed by normalizations against β-actin in 
C. D: PSR staining depicting fibrosis at 24 h, 48 h, 1 wk, and 4 wk in the DIO + BDCM 




Figure 2.10 Schematic representation of the role of leptin-induced miR21 in modulating 
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Abstract: 
Although significant research data exist on the pathophysiology of nonalcoholic 
steatohepatitis (NASH), finding an efficient treatment regimen for it remains elusive. The 
present study used sparstolonin B (SsnB), a novel TLR4 antagonist derived from the 
Chinese herb Sparganium stoloniferum, as a possible drug to mitigate early inflammation 
in NASH. This study used an early steatohepatitic injury model in high-fat-fed mice with 
CYP2E1-mediated oxidative stress as a second hit. SsnB was administered for 1 wk 
along with bromodichloromethane (BDCM), an inducer of CYP2E1-mediated oxidative 
stress. Results showed that SsnB administration attenuated inflammatory morphology and 
decreased elevation of the liver enzyme alanine aminotransferase (ALT). Mice 
administered SsnB also showed decreased mRNA expression of proinflammatory 
cytokines TNF-α, IFN-γ, IL-1β, and IL-23, while protein levels of both TNF-α and IL-1β 
were significantly decreased. SsnB significantly decreased Kupffer cell activation as 
evidenced by reduction in CD68 and monocyte chemoattractant protein-1 (MCP1) 
mRNA and protein levels with concomitant inhibition of macrophage infiltration in the 
injured liver. Mechanistically, SsnB decreased TLR4 trafficking to the lipid rafts, a 
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phenomenon described by the colocalization of TLR4 and lipid raft marker flotillin in 
tissues and immortalized Kupffer cells. Since we have shown previously that NADPH 
oxidase drives TLR4 trafficking in NASH, we studied the role of SsnB in modulating this 
pathway. SsnB prevented NADPH oxidase activation in vivo and in vitro as indicated by 
decreased peroxynitrite formation. In summary, the present study reports a novel use of 
the TLR4 antagonist SsnB in mitigating inflammation in NASH and in parallel shows a 
unique molecular mechanism of decreasing nitrative stress. 
Keywords: SsnB, inflammation, NADPH oxidase, p47phox, peroxynitrite 
3.1 INTRODUCTION 
Nonalcoholic steatohepatitis (NASH), a hepatic manifestation of metabolic syndrome, 
arises from an underlying condition of obesity (73). 
After nearly three decades there remains a void of drugs approved for the 
treatment of NASH. Although sufficient progress in the understanding of 
pathophysiology, diagnosis, and stages of the disease has been made, a treatment regimen 
to cure this metabolic disease remains a challenge. Several treatment modalities have 
been tried, yet no single approach has been found to be effective in treating NASH (74). 
Lipid-lowering drugs like fibrates and statins have some effect, while insulin sensitizers 
(metformin, thiazolidinediones), endocannabinoid receptor agents, ursodeoxycholic acid, 
and green tea polyphenols have mixed effects (75). Results from both preclinical and 
clinical trials distinctly point to a combinatorial approach (caloric restriction, anti-
inflammatory, and antioxidant) as a therapeutic remedy for NASH (76-78). Therefore 
there is a dire need for sustained research and drug discovery efforts that aim at 
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identifying new targets for therapy and eventually combine those that target concomitant 
and synergistic pathways of NASH pathogenesis. 
As for alcoholic steatohepatitis, Toll-like receptors (TLRs) have been shown to be 
involved in the pathogenesis of NASH, as reviewed recently (79, 80). A pioneering study 
by Farhadi et al. (81) reported endotoxemia resulting from possible gut leakiness as a 
cause for NASH. Later, many reports emerged about the involvement of endotoxin from 
the gut as a cause for activation of the TLR4 receptors and the downstream inflammatory 
pathways(81-94). We have recently shown (24) that peroxynitrite, a nitrative species 
formed from the reaction between superoxide and nitric oxide, is responsible for TLR4 
recruitment in lipid rafts. Lipid raft trafficking of TLR4 remains a significant step in 
TLR4 signaling and inflammation (95, 96). Upon binding to the TLR4 ligand, it is 
rapidly assembled in the lipid-containing domains, an event that is facilitated by NADPH 
oxidase (95). Our previously published observations (24) point to the role of peroxynitrite 
in contributing to the trafficking of TLR4 in rafts primarily following NADPH oxidase 
activation in NASH livers. Abrogation of TLR4 trafficking significantly decreased 
inflammation in NASH models and had improved histological outcomes (24). Several 
research reports in the past have described TLR4 antagonists and their effectiveness in 
attenuating TLR4-based inflammation in disease models (97). Unfortunately, none could 
be recommended for therapeutic use in humans. However, the search for an effective 
TLR4 antagonist continues owing to the importance of the TLR4 pathway in a myriad of 
diseases. 
Extending this endeavor in search of an effective TLR4 antagonist, our 
collaborators have recently published several research studies that report the effective 
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TLR4-antagonizing role of sparstolonin B (SsnB), a natural product derivative (28, 98-
104). SsnB, an isocoumarin, was isolated from a Chinese herb, Sparganium stoloniferum; 
its structure was determined by NMR spectroscopy and X-ray crystallography (28). In 
light of the above evidence of SsnB being a potent antagonist for TLR4-induced 
inflammation and tissue injury, we tested the hypothesis that administration of SsnB in 
murine models of NASH and immortalized Kupffer cells will attenuate early 
inflammation and tissue injury induced by TLR4 activation. In the present study we used 
a rodent model of NASH in which oxidative stress mediated by CYP2E1, lipotoxicity, 
and innate immune mediators were used as “second/multiple hits” to cause NASH. 
Results showed that SsnB significantly attenuated TLR4 trafficking to the lipid rafts, a 
significant event in TLR4 activation. The effects of SsnB on TLR4 trafficking were also 
correlated with a significant inhibition of NADPH oxidase activation and peroxynitrite 
formation, an event that was reported by us to be upstream of TLR4 activation in NASH 
though TLR4-induced NADPH oxidase activation. 
3.2 MATERIALS AND METHODS 
Cell culture: Rat immortalized kupffer cell line (Applied Biological Materials Inc., 
Canada) was maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM, 
Corning, VA) supplemented with 10% fetal bovine serum (FBS, Atlas Biologicals, CO) 
and 1x Penicillin-Streptomycin solution (Gibco, Life Technologies, NY), and grown at 
37°C in a humidified incubator with 5% CO2. HBSS buffer, Tissue culture plastic wares 
were purchased from Corning (Corning, VA). Sparstolonin B (SsnB) compound was a 
kind gift from our collaborator Dr. Daping Fan (Cell Biology and Anatomy, University of 
South Carolina School of Medicine).Stock solution of SsnB was prepared in dimethyl 
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sulfoxide (DMSO). The final concentration of SsnB on cells was 100µg/ml, 0.1% 
DMSO. The cells were plated on 12 well plates (100,000/well) using DMEM medium 
supplemented with 10% FBS. Before treating the cells with LPS (50ng/ml), Leptin 
(100ng/ml) and SsnB (100µg/ml), cells were serum starved (DMEM with 0.25% FBS) 
for overnight. All treatments are given for 24 hours in 0.25% FBS containing DMEM 
medium. Cells treated with 0.1% DMSO were used as control. Cells treated with Leptin 
(BioVision, CA) and LPS (Sigma, MO) also had 0.1% DMSO. The cell supernatant was 
collected for Nitiric oxide quantification. Cells were plated on coverslips by putting the 
coverslips on each well of 12 well plates maintaining the aforementioned conditions and 
the cells adhered on coverslips were used for immune-fluorescence dual labelling 
staining after completion of the treatment. Primary mice (C57BL6) hepatic macrophages 
(ScienCell research lab, Carlsband, CA) were cultured in macrophage specific MaM 
media supplemented with MAGS, FBS and P/S (ScienCell research lab, Carlsband, CA) 
as instructed by the manufacturer on poly-L-lysine (ScienCell research lab, Carlsband, 
CA) coated 12 well plates and incubated at 37°C in a humidified incubator with 5% CO2 
to initiate the culture. The cell culture medium was replaced with fresh media in the next 
morning and the cells were treated with LPS, LPS and SSnB maintaining the same 
concentration and incubation time as mentioned above. Cells, treated with 0.1% DMSO 
were used as control. 
Mouse Models: Pathogen free, male, C57BL/6J background mice (purchased from 
Jackson Laboratories, Bar Harbor, ME) were housed one per cage with a 12-h/12-h 
light/dark cycle at 23-24°C at libitum access to food and water. These mice were fed with 
60% kcal high fat diet (purchased from Research Diets, New Brunswick, NJ) from 6 
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weeks until 16 weeks to generate a model of steatosis (S). Another group of these high fat 
diet fed mice, were administered Bromodichloromethane BDCM (1mmol/kg, diluted in 
corn oil) intraperitoneally, twice a week for 1 week to generate toxin induced early 
steatohepatitic injury model of mice (SH). BDCM and corn oil were purchased from 
Sigma-Aldrich (St. Louis, MO).A set of high fat diet fed, BDCM treated mice were 
administered with SsnB (3mg/kg-bw) intraperitoneally twice for 1 week (SH+SsnB). A 
group of steatotic mice was also administered with SsnB (3mg/kg-bw) intraperitoneally 
twice for 1 week (S+SsnB). Age-matched lean control mice (LC) were fed with chow 
diet having 10% kcal fat. Another group of chow diet fed lean mice was treated with 
same dosage of BDCM for 1 week (LC+BDCM). All animals were treated in strict 
accordance with the NIH guideline for Humane Care and Use of Laboratory Animals and 
local IACUC standards. All experiments were approved by the institutional review board 
at NIEHS, Duke University and the University of South Carolina at Columbia. After 
completion of the treatment, mice belonging to all groups were sacrificed for liver tissues 
and serum samples for further experiments. 
Laboratory analysis 
Immunohistochemistry: Mice livers were collected and fixed in 10% neutral buffered 
formalin (Sigma Aldrich, Missouri, USA). These formalin-fixed tissues were paraffin 
embedded and cut in 5μm thick sections. Using standard protocol (53), these liver 
sections were deparaffinized. The deparaffinized sections were subjected to epitope 
retrieval of was performed using epitope retrieval solution and steamer (IHC-World, 
Woodstock, MD) following the manufacturer’s instructions. The endogenous peroxidases 
were blocked by 3% H202. Anti-mouse primary antibodies like anti–IL1β, anti–TNFα, 
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anti-MCP1, anti-F4/80, anti-3 Nitrotyrosine (Abcam, Cambridge, MA) were used in 
recommended dilutions. Following manufacturer’s protocols (Vectastain Elite ABC kit, 
Vector Laboratories, Burlingame, CA), biotinylated conjugated secondary antibody 
(species specific) and streptavidin conjugated with HRP were used to perform antigen-
specific immunohistochemistry. 3, 3’ Diaminobenzidine (Sigma-Aldrich, St.Louis, MO) 
was used as chromogenic substrate. Mayer’s hematoxylin (Sigma-Aldrich) was used as 
counterstain. Phosphate buffer saline was used for washing three times between the steps. 
Finally, the sections were mounted in Simpo mount (GBI Laboratories, Mukilteo, WA) 
and observed under a 20x objective using an Olympus BX51 microscope (Olympus, 
America). Morphometric analysis was done using CellSens Software from Olympus 
America (Center Valley, PA). 
Haematoxylin and Eosin staining: Formalin-fixed tissues were paraffin embedded liver 
tissue sections were stained with Haematoxylin and Eosin by the IRF, University of 
South Carolina, and School of Medicine. 
Serum ALT: Serum samples collected from mice were subjected to alanine 
aminotransferase (ALT) analysis (Discovery Life Sciences, CA) according to 
manufacturer’s instructions. 
Nitric oxide quantification assay: After treating the rat kupffer cells with LPS and 
LPS+SsnB (mentioned before), the cell supernatants were collected. The supernatant 
collected from the wells, where cells were not treated with LPS or LPS+SsnB, served as a 
control. Nitrite was measured in these samples by Griess Reagent System (Promega, WI) 
following the manufacturer’s instructions. 
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ELISA: After treating the primary mice hepatic macrophages with LPS and LPS+SsnB 
(mentioned before), the cell supernatants were collected. The supernatant collected from 
the wells, where cells were not treated with LPS or LPS+SsnB, served as a control. TNFα 
concentration was measured in these samples by using Mouse TNF ELISA kit (BD 
Biosciences, San Jose, CA) following the manufacturer’s instruction. 
Immunofluorescence dual-labeling  
In vivo: Formalin-fixed, paraffin embedded tissues sections were subjected to 
deparaffinization using standard instructions. Epitope retrieval of the deparaffinized 
sections was done using epitope retrieval solution and steamer (IHC-World, Woodstock, 
MD) following the manufacturer’s protocol. The primary antibodies anti-gp-91phox, 
anti-p47phox, Flottilin1, TLR4 (purchased from Santa Cruz biotechnology, Inc. Santa 
Cruz, CA and Abcam, Cambridge, MA) and used at recommended dilutions. Species-
specific anti-IgG secondary antibodies conjugated with Alexa Fluor 488(Invitrogen, 
California, USA) was used against anti-p47phox, anti-flottilin1 and Alexa Fluor 633 
(Invitrogen, California, USA) was used against anti-gp91 phox and TLR4 respectively. 
The sections were mounted in a ProLong gold antifade reagent with DAPI (Life 
technologies, EU, OR). Images were taken under 20x and 60x oil objectives using 
Olympus BX51 microscope. 
In vitro: After completion of the treatments under serum starved condition as the 
aforementioned cell culture section, cells attached on coverslips were fixed using 10% 
Neutral Buffer Saline. After washing the cells with PBS, containing 0.1% triton x 
(Sigma, MO) the cells were blocked using 3% BSA, 0.2% Tween (Fisher, NJ), 10% FBS 
51 
 
in PBS. Cells were incubated with primary antibodies anti-gp91 phox, anti-p47 phox, 
anti-TLR4 (mentioned earlier) and anti-flotillin 2 (Abcam, Cambridge, MA), followed by 
species specific Alexa Fluor 633 and 488 (mentioned earlier), for immune-fluorescence 
dual labelling staining. Alexa Fluor 633 was used against anti-TLR4 and anti-gp91 phox. 
Alexa Fluor 488 was used against anti-flottilin2 and anti- p47 phox. The stained cells 
attached on the coverslips were mounted on slides using ProLong gold antifade reagent 
with DAPI (Life technologies, EU, OR) and viewed under 40x and 60x oil objectives 
using Olympus BX51 microscope. 
Quantitative Real-Time Polymerase Chain Reaction: Gene expression (mRNA) levels 
in the mice liver tissue samples and mouse primary hepatic macrophages were measured 
by real-time reverse transcription-polymerase chain reaction (qRTPCR). Total RNA was 
isolated from liver tissues and mouse primary hepatic macrophages using TRIzol reagent 
(Life Technologies, Carlsbad, CA). Trizol reagent is used to lyse the tissue, RNA 
extraction and purification are carried out by using RNeasy mini kit columns (Qiagen, 
Valencia, CA) following manufacturer’s protocol. 1µg of purified RNA was converted to 
cDNA by using iScript cDNA synthesis kit (Bio-rad, Hercules, CA). Quantitative real-
time reverse transcription-polymerase chain reaction was performed with the gene 
specific primers using CFX96 thermal cycler (Bio-Rad, Hercules, CA) and SsoAdvanced 
universal SYBR Green supermix (Bio-Rad, Hercules, CA). Threshold Cycle (Ct) values 
for genes of interest were normalized against 18S (internal control) values in same 
sample. Reaction was carried out in triplicates for each gene and each tissue sample. The 
relative fold change was calculated by the 2-∆∆Ct method.  The mouse specific primers 
used for Real time PCR in 5’to 3’ orientation are IL1β (Forward: 
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CCTCGGCCAAGACAGGTCGC, Reverse TGCCCATCAGAGGCAAGGAGGA), 
TNFα (Forward: CAACGCCCTCCTGGCCAACG, Reverse: 
TCGGGGCAGCCTTGTCCCTT), IFNγ (Forward: TGCGGGGTTGTATCTGGGGGT, 
Reverse: GCGCTGGCCCGGAGTGTAG), IFNγ (Forward: 
TGCGGGGTTGTATCTGGGGGT, Reverse: GCGCTGGCCCGGAGTGTAG), IL23 
(Forward: AAAGGATCCGCCAAGGTCTG, Reverse: 
GCAGGCTCCCCTTTGAAGAT), CD68 (Forward: 
GCTACATGGCGGTGGAGTACAA, Reverse: ATGATGAGAGGCAGCAAGATGG), 
MCP1(Forward: CACAGTTGCCGGGCTGGAGCAT, Reverse: 
GTAGCAGCAGGTGAGTGGGGC),  P47phox (Forward: 
GGTCGACCATCCGCAACGCA, Reverse: TGTGCCATCCGTGCTCAGCG), TLR4 
(Forward: GGAGTGCCCCGCTTTCACCTC, Reverse: 
ACCTTCCGGCTCTTGTGGAAGC). 
miRNA21 expression levels in liver tissues: Liver tissues were homogenized in Qiazol 
reagent (Qiagen, Valencia, CA) following the manufacturer’s instructions to isolate the 
total miRNA. The purification was done by using miRNeasy mini kit columns (Qiagen, 
Valencia, CA). 100ng of purified miRNA was converted to cDNA using miScript cDNA 
synthesis kit (Qiagen, Valencia, CA) using the manufacturer's protocol. qRTPCR was 
performed with microRNA specific primers (Qiagen, Valencia, CA) using miScript 
SYBR Green PCR master mix (Qiagen, Valencia, CA) and CFX96 thermal cycler (Bio-
rad, Hercules, CA). Threshold Cycle (Ct) values for the selected gene was normalized 
against RNU6-2 (internal miRNA expression control) values in the same sample. 
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Western Blotting: In the presence of phosphatase and protease inhibitors (Pierce, 
Rockford, IL), 30 mg of each liver tissue was homogenized in 500 µl of RIPA buffer 
(Sigma Aldrich) by using dounce homogenizer. The homogenate was centrifuged and the 
supernatant was collected for further experiments. 25 µg of each protein sample was 
loaded on 4–12% bis-tris gradient gel (Invitrogen, California, USA) for SDS PAGE. By 
using precut nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories Inc., 
California, USA ) and Trans – Blot Turbo transfer system (Bio-Rad), proteins were 
transferred to nitrocellulose membrane. Blots were blocked with 5% non-fat milk 
solution. Primary antibody against PTEN, β-actin (purchased from Abcam, MA) and 
TLR4 (Santa Cruz Biotechnology, CA) were used at recommended dilutions and 
incubated overnight at 4ºC. Species specific secondary antibodies conjugated with HRP 
(Abcam, MA) were used and the blots were incubated at room temperature for 2 hours. 
Pierce ECL Western Blotting substrate (Thermo Fisher Scientific Inc., Rockford, IL) was 
used. The blot was developed by using BioMax MS Films and cassettes (with 
intensifying screen, Kodak). Densitometry analysis of the images was done using Lab 
Image 2006 Professional 1D gel analysis software from KAPLEAN Bioimaging 
Solutions (Liepzig, Germany). 
Statistical Analyses: The statistical analysis was performed by analysis of variance 
(ANOVA) which was followed by Bonferroni post-hoc correction for intergroup 






SsnB administration attenuates early steatohepatitic injury in obese mice. Feeding 
high fat diet to C57BL6/J mice for 4 weeks starting from 8 weeks post gestational age 
causes insulin and leptin resistance, steatosis but does not cause inflammation, tissue 
injury and fibrosis(40). Nonalcoholic steatohepatitis (NASH) can be a result of multiple 
hits that may include oxidative stress, increased CYP2E1 activity, cytokine release and/or 
altered metabolism(105). We used a toxin-induced steatohepatitis and lipotoxicity model 
in mice to show the therapeutic effects of SsnB(38) . Results showed that SsnB 
administration markedly decreased necrosis, ballooning, Mallory denk bodies and 
inflammatory foci in steatohepatitis group (SH) (Figure 3.1 A). SsnB administration 
significantly decreased the levels of serum ALT as compared to SH group but was 
significantly higher than the steatosis (S) group (Figure 3.1 B) (P<0.05). 
NASH is known to have a significant proinflammatory phase primarily arising 
from activation of pattern recognition receptors (PRRs) in the liver primarily from higher 
endotoxin levels, HMGB1 or other endogenous ligands(90, 106). To study the effect of 
SsnB administration to SH mice, liver proinflammatory cytokine gene and protein levels 
were analyzed by qrtpcr and immunohistochemistry. Results showed that as expected, 
mRNA expression of TNF-α, IFN-γ and IL1β, which are proinflammatory in nature were 
significantly elevated in SH group as compared to S only group (Figure.3.2A)(P<0.05). 
IL23 is known as a marker for M1 polarization(107, 108). Results showed that mRNA 
expression of IL23 also was significantly upregulated in SH group when compared to S 
only group (Figure.3.2A)(P<0.05). SsnB administration significantly decreased the 
mRNA expression of proinflammatory markers TNFα, IFNγ, IL1β and macrophage 
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polarization marker IL23 when compared to SH group (Figure.3.2A)(p<0.05). Since 
TLR4 activation has been shown to be major event in progression of nonalcoholic 
steatohepatitis we studied the downstream proinflammatory molecules for this important 
pathway. Results showed that there was a significant increase in TNF-α and IL1β 
immunoreactivity in liver slices from SH mice when compared to S group only 
(Figure.3.2B, C and D)(P<0.05). The localization of the cytokines was unevenly 
distributed with TNFα localized in the centrilobular regions while IL1β at both Zone1 
and Zone 3 respectively (Figure.3.2B). SsnB administration significantly decreased the 
immunoreactivity of both TNFα and IL1β in liver tissue when compared to SH group 
mice (Figure3.2B, C and D)(P<0.05).  
SsnB administration modulates Kupffer cell activation in early steatohepatitic 
injury. NASH is associated with activation of the resident macrophages in the liver(40). 
Kupffer cells has been shown to migrate more towards Zone-3 in liver injury, generate 
reactive oxygen species, release proinflammatory cytokines and chemokines and play a 
significant role in inflammatory mechanisms in NASH(44). We examined the role of 
SsnB in modulating Kupffer cell activation in vivo by studying the mRNA and 
immunoreactivity of Kupffer cell activation marker CD68 and monocyte chemoattractant 
protein-1 (MCP-1) in the injured livers. Results showed that SsnB administration 
significantly decreased mRNA expression of both CD68 and MCP-1 (decrease of more 
than 12 fold for CD68) (Figure.3.3A) (P<0.05). Immunoreactivity to MCP1 were also 
significantly decreased in SH mice that were administered SsnB when compared to SH 
mice alone suggesting a possibility of low leukocyte infiltration in the liver lobule 
(Figure 3.3B, upper panel, C-morphometric analysis) (P<0.05). To examine the extent of 
56 
 
leukocyte infiltration in the liver lobule immunoreactivity to pan macrophage marker 
F4/80 was studied using immunohistochemistry. Results showed that there were 
significant increases in F4/80 immunoreactivity in the injured liver when compared to S 
group alone while administration of SsnB significantly attenuated the leukocyte 
infiltration as evidenced by decreased immunoreactivity to F4/80 in the liver (Figure. 3.3 
B-down panel, 3D-morphometry) (p<0.05). 
SsnB administration attenuates miR21 expression and repression of phosphatase 
and Tensin homologue (PTEN). We have shown previously that steatohepatitic injury 
following obesity causes a marked increase in miR21 expression, a non-coding RNA that 
has significant regulatory role in liver inflammation(109, 110). Higher miR21 levels led 
to decreased GRHL3 and SMAD7 proteins in both human NASH and rodent models of 
obesity(109, 110). Since TLR4 has been shown to play a role in miR21 induction, we 
studied the effects of SsnB, a probable TLR4 antagonist in TLR4-induced miR21 
pathway. Results showed that SH mice had a significant increase in mir21 expression 
while administration of SsnB markedly decreased its expression in the murine obese liver 
(over 3 fold decrease) (Figure 3.4A)(P<0.05). SsnB administration also decreased the 
levels of PTEN, a direct target of miR21 in the liver as shown by western blot analysis 
when compared to SH group (Figure 3.4B and C)(P<0.05). The results suggested that 
SsnB might have a role in decreasing miR21 induced repression of PTEN primarily by 
blocking TLR4 activation however the interpretation of a SsnB role in blocking TLR is 
speculative at this time. 
SsnB targets TLR4 trafficking to lipid rafts. Many studies, including ours have shown 
a direct role of TLR4 activation in both alcoholic and nonalcoholic steatohepatitis (80, 
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95, 111). One of the key aspects of TLR4 activation is its trafficking to lipid rich domains 
on the plasma membrane(95). Upon binding to a specific TLR4 ligand which can include, 
lipopolysaccharide (LPS), HMGB1 or free fatty acids, TLR4 protein is translocated to 
lipid containing rafts where the association to adaptor proteins and membrane assembly 
take place. Our collaborators in this study have shown via direct evidence that SsnB 
disrupts TLR4 activation and can be a potent TLR4 antagonist. To show the mechanistic 
insight of SsnB action in steatohepatitic liver injury, we studied the TLR4 trafficking into 
lipid rafts and its disruption by SsnB. Results showed that SsnB administration 
significantly decreased the colocalization of TLR4 (red) and lipid raft component flotillin 
(green) in the plasma membrane of SH mice (Figure 3.5A). The number of colocalization 
events/microscopic field were significantly decreased in SsnB treated group as compared 
to SH mice livers (Figure 3.5 B)(P<0.05). The results suggested that SsnB has a 
significant role in TLR4 trafficking in early steatohepatitic injury and the modulation of 
TLR4 trafficking might be contributing in part for the attenuation of inflammation seen 
with SsnB administration. Since resident macrophages play a clear role in liver 
inflammation in NASH, we studied the TLR4 trafficking in immortalized Kupffer cells 
following their stimulation with LPS, the classical ligand of TLR4. Results showed that 
incubation of Kupffer cells with LPS (50ng/ml) significantly increased colocalization of 
TLR4 with lipid raft marker flotillin while co-incubation with SsnB (100µg/ml) 
significantly attenuated the TLR4 translocation to the rafts (Figure. 3.6A and B). The 
SsnB co-incubation resulted in a 3 fold decrease in the colocalization events (Figure. 3.6 
B(P<0.05). The colocalization is also shown in higher magnification (Figure. 3.6C) 
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SsnB targets leptin induced TLR4 trafficking in Kupffer cells. We have shown 
previously that proinflammatory adipokine leptin regulates Kupffer cell activation via 
reactive oxygen species generation(40). Leptin increased peroxynitrite generation by 
increasing NADPH oxidase activation that resulted in higher inflammatory mediation. 
Since hepatic leptin resistance is a common phenomenon in NASH patients, and  
selective leptin signaling observed in hepatic stellate cells, we studied the role of leptin in 
TLR4 trafficking to the lipid rafts in vitro(112, 113). Results showed that leptin 
administration to immortalized Kupffer cell culture significantly increased the TLR4-
Flotillin colocalization as  evidenced by yellow spots on the membranes of the incubated 
cells (Figure 3.7A-40x and C-60x oil images showing clusters of cells with colocalization 
in the membranes). Analysis of the number of colocalization events showed a significant 
increase in leptin-treated group when compared to cell-only controls (Figure 3.7A and 
B)(P<0.05) with a 4 fold increase recorded in this group. SsnB co-incubation with leptin 
significantly decreased the colocalization events in these cells (Figure 3.7A and B) 
(P<0.05). The results suggested that similar to LPS, TLR4 trafficking to the lipid rafts 
was also influenced by leptin, a proinflammatory adipokine with known effects in NASH. 
Though the mechanism of leptin action via TLR4 ligand binding is highly unlikely in 
these cells, SsnB modulation of leptin might be an upstream event and can be a common 
target for SsnB apart from being a strong antagonist for TLR4 activation. 
SsnB attenuates NADPH oxidase activation and peroxynitrite generation. Since 
SsnB administration significantly decreased TLR4-induced hepatic inflammation in 
obesity both in response to LPS and leptin, we argued about the presence of a significant 
target upstream of the TLR4 pathway that might be common and conspicuous for both 
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leptin and LPS mediated signaling. We recently showed that TLR4-lipid raft trafficking 
in NASH was mediated by peroxynitrite generated by the activation of NADPH 
oxidase(111). To show that SsnB modulated NADPH oxidase activation and 
peroxynitrite generation, events that are upstream of TLR4 activation, colocalization 
analysis of NADPH oxidase membrane subunits in the membranes of liver tissue were 
studied by immunofluorescence microscopy. Results showed that p47 phox (green), a 
cytoplasmic subunit required for NADPH oxidase activation colocalized with gp91 (red) 
a membrane subunit in liver tissue (Figure 3.8A-20x and C-60x oil images showing 
colocalization clusters). Analysis of the number of colocalization events in the liver tissue 
showed a significant increase in SH treated group while SsnB treated mice liver showed a 
significant decrease in the colocalization events suggesting a decreased NADPH oxidase 
activation (Figure 3.8B)(P<0.05). Kupffer cells treated with both leptin and LPS showed 
a marked increase in the gp91/p47 phox colocalization events while administration of 
SsnB (100 µg/ml) resulted in a significant decrease of the events (Figure 3.8D). Since 
NADPH oxidase activation resulted in generation of peroxynitrite in NASH, we 
examined the formation of 3-Nitrotyrosine, a marker for peroxynitrite generation in the 
diseased liver and immortalized Kupffer cells. Results showed that 3-nitrotyrosine 
immunoreactivity as analyzed by immunohistochemistry was significantly increased in 
SH mice livers as compared to S only group (Figure 3.9A and B)(P<0.05). SsnB 
administered mice livers showed a significant decrease in the 3-nitrotyrosine 
immunoreactivity when compared to SH mice livers (Figure 3.9A and B)(P<0.05). Since 
peroxynitrite generation requires both O2
.- and NO• reactivity in equal diffusion 
controlled rates, we studied the release of NO• from the Kupffer cell supernatants 
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incubated with both leptin, LPS and SsnB. Results showed that LPS and Leptin 
significantly increased NO• release while co-incubation with SsnB significantly 
attenuated the release of NO• analyzed by Greiss assay (Figure 3.9C)(P<0.05). The 
results suggested that apart from the strong TLR4 pathway antagonism function of SsnB, 
it also plays a significant role in NADPH oxidase activation and NO• release in 
inflammation. The SsnB attenuation of TLR4 pathway might be in part related to its 
effect on NADPH oxidase activation that is upstream of TLR4 trafficking to lipid rafts. 
SsnB attenuates TLR ligand-induced gene expression of inflammatory cytokines, 
p47 phox, CD68 and cytokine release in mouse primary hepatic macrophages. To 
see the direct effect of SsnB on mouse primary hepatic macrophages, qRT PCR was 
performed to measure the pro-inflammatory cytokine gene expression levels. Result 
showed that as expected, mRNA expression of IL1β, MCP1 and TNFα pro-inflammatory 
cytokine gene expression were significantly elevated in LPS treated cells compared to 
untreated control cells. However, co-incubation of LPS treated cells with SsnB, decreases 
the expression of these genes significantly compared to only LPS treated cells (Figure 
3.10A). In another set of experiments, after the mice primary hepatic macrophages were 
treated with SsnB and LPS for 24 h, the supernatant was collected for measurement of 
TNFα cytokine concentration by ELISA. As shown in Figure 3.10B, in TNFα level in the 
control media was almost undetectable. LPS (50 ng/ml) treatment dramatically increased 
the TNFα cytokine level. However, co-incubation with SsnB significantly reduced the 
TNFα cytokine level (Figure 3.10B). We have shown previously in Figure 3.8 and Figure 
3.9 that SsnB significantly reduces the formation of peroxynitrite and corresponding 
inflammation and Kupffer cell activation by decreasing the co-localization of gp91/p47 
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phox and thus attenuates NADPH oxidase activation. To see whether SsnB has any effect 
in attenuating p47phox gene expression, a quantitative-real time PCR was performed to 
measure the p47phox gene expression levels. Result showed that mRNA expression of 
p47 phox gene expression was significantly elevated in LPS treated cells compared to 
untreated control cells (Figure 3.10C). However, co-incubation with SsnB, decreases the 
expression of these genes significantly compared to only LPS treated cells.  
SsnB treatment does not reduce TLR4 gene expression or protein concentration. To 
address the question whether SsnB acts by decreasing TLR4 mRNA expression, qRT 
PCR experiments were performed to quantify the TLR4 mRNA expression both invivo 
and invitro. Our data shows that SsnB administration may slightly attenuated the up-
regulation of TLR4 mRNA levels compared to SH group (Figure.3.11A). Co-incubation 
of mice primary hepatic macrophages with SsnB also resulted a faint reduction of TLR4 
mRNA expression compared to only LPS treated cells (Figure 3.11B). Liang et al., (28) 
observed the similar incident and described it as a secondary event to the suppression of 
pro-inflammatory signaling pathways. A western blot experiment was also performed 
from mice liver homogenates to see if TLR4 protein expression is reduced by SsnB 
administration. Our data clearly indicates that SsnB administration didn’t cause any 
reduction in total TLR4 protein level (Figure. 3.11C and D). However, it has already been 
shown by Liang et al., (28) that SsnB possibly acts by attenuating the interaction of 
MyD88 and TLR4 Toll/interleukin-1 receptor (TIR) domain. Our findings also suggest 
that SsnB decreases TLR4 trafficking in lipid rafts by preventing NADPH oxidase 
activation and reducing nitrative stress. Thus there is a possibility that SsnB induced 
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TLR4 signaling attenuation may not be dependent on the total TLR4 protein 
concentration. 
3.4 DISCUSSION: The present study reports a novel role and mechanistic insight of the 
TLR4 antagonist SsnB. Using a rodent model of early steatohepatitic injury, we show 
that SsnB attenuated inflammation in the liver by blocking TLR4 trafficking to the lipid 
rafts. Further, we deciphered that SsnB could block TLR4 trafficking into the lipid rafts 
by decreasing NADPH oxidase activation and peroxynitrite generation. The role of TLR4 
in NASH and its consequences is being pursued vigorously across the scientific 
community(79, 80, 114). The potent role of TLR4 activation and its downstream 
signaling has been reported in both alcoholic and nonalcoholic steatohepatitis(79). In 
alcoholic steatohepatitis, portal endotoxemia from gut leaching has been accepted as a 
source for the TLR4 ligand in the liver(87, 115). Various studies have reported free fatty 
acids and HMGB1 as ligands in TLR4 activation in NASH(95, 116, 117). We recently 
reported that peroxynitrite generation activates TLR4 signaling by modulating its 
trafficking into the lipid rafts primarily by an upstream NADPH oxidase activation(111). 
The results in that study also confirmed an earlier report showing NADPH oxidase as a 
prime regulator of TLR4 trafficking but could not provide a molecular mediator for its 
actions (95). Interestingly TLR4 downstream signaling is also known to produce NADPH 
oxidase activation(118). Our results in this report show a novel role of SsnB, a natural 
product derivative in modulating TLR4 trafficking into lipid rafts, a mechanism that 
remained elusive before. SsnB has been shown by our collaborators in numerous in vivo 
and in vitro studies to be a portent TLR4 antagonist(28, 98-101, 119). SsnB structural 
analysis and its characterization in terms of mechanism of action showed that it reduced 
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the association of  MyD88 with TLR4 and TLR2 but not with TLR9(28). Inflammatory 
cytokine signaling emanating from the TLR4 signaling in vitro was specifically blocked 
by SsnB while LPS-induced septic shock was reversed by its administration in vivo(101). 
Having known the earlier reported mechanisms of SsnB action we explored its role in 
NASH induced inflammatory injury. Our rationale was based on the strong inflammatory 
phase in NASH that is appreciated in both rodent models of NASH and clinical 
phases(120). Our results showed that SsnB administration in vivo reversed inflammatory 
pathophysiology primarily evidenced by reduced leukocyte infiltration, decreased 
necrosis in Zone3 and lower levels of proinflammatory cytokines IL1β and TNF-α. Since 
Kupffer cell activation is a prime inflammatory event in NASH that also has been shown 
to play a vital role in activating stellate cells, we examined the levels of CD68 and MCP-
1. Results showed a dramatic decrease in the levels of the chemokines and surface 
expression of CD68. The results were in line with earlier reports from our lab and others 
that Kupffer cell activation reversal can have a beneficial effect on NASH progression 
and treatment at least in rodent models of NASH(40, 114). The studies reported here 
however have not explored the role of SsnB in reversal of Kupffer cell activation since 
we knew that SsnB might target TLR4 that has been shown previously to activate 
Kupffer cells(121).  Though Kupffer cells respond to LPS mediated TLR4 activation, 
there are reports of TLR4 expression in hepatocytes, endothelial cells and stellate 
cells(79, 90).Interestingly, Kupffer cells are primary foci for generating an inflammatory 
response and SsnB action in these cells might mediate the TLR4 activation.. The SsnB 
role in preventing TLR4 signaling in Kupffer cells might render a stalling effect on the 
initial inflammatory phase which may eventually block stellate cell activation and 
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extracellular matrix formation. For the purposes discussed above we used immortalized 
Kupffer cells to illustrate the mechanism of SsnB deactivation of TLR4 pathway. 
We have recently shown that NASH is characterized by an increase in miR21 
induced repression of GRHL3 and SMAD7, two key proteins that have a pronounced role 
in sinusoidal endothelial injury and extracellular matrix formation (109, 110). 
Interestingly miR21 is a TLR4 inducible non coding RNA and our results in this report of 
a significant decrease in miR21-induced repression of PTEN confirmed the SsnB 
targeting of TLR4 pathway(58). It will be of interest in later studies, how SsnB may help 
in alleviating the miR21-induced repressions of GRHL3 and SMAD 7 in NASH.  
To mechanistically explain the role of SsnB in TLR4 deactivation response we 
studied the trafficking of TLR4 into lipid rafts which is a prime event in TLR4 activation 
and downstream signaling(95). Lipid raft are lipid rich domains within the plasma 
membrane that help in assembly of many transmembrane receptors including TLR4(95). 
This myriad of molecular events and assembly starts with the binding of an appropriate 
ligand to TLR4. We observed that SsnB administration significantly attenuated the 
trafficking of TLR4 into lipid rafts as shown by decreased number of colocalization 
events (TLR4 and flotillin) in NASH livers. Rat immortalized Kupffer cells were also 
used to show the trafficking process and its attenuation by SsnB following TLR 
stimulation by LPS. Our results of significant decrease in colocalization events of TLR4 
and flotillin in Kupffer cells show that SsnB could exert its TLR4 antagonism by stalling 
the lipid raft recruitment process. Though SsnB has been shown by our collaborators to 
interfere in the association of TLR4 with its adaptor MyD88, It can be speculated that 
SsnB could competitively bind to TLR4 thus restricting the classical ligand LPS to exert 
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its effects(28). However this observation is highly speculative at this point since SsnB 
binding to TLR4 in NASH has not been studied. Interestingly TLR4 trafficking to rafts 
occur on binding of the ligand to TLR4 and it would be interesting to see the molecular 
aspects of SsnB binding to TLR4 or its restrictive capacity to alter TLR4 ligand binding 
in future studies. 
We have shown previously that proinflammatory adipokine leptin mediates the 
progression of NASH by activating Kupffer cells, upregulation of non-coding RNAs and 
activating pattern recognition receptor P2X7r(109, 110). Leptin has been shown recently 
to upregulate TLR2 expression in monocytes (122). Extending the studies of leptin 
induced proinflammatory action in Kupffer cells we studied their role in activating TLR4 
trafficking in these cells. Results showed that leptin activated TLR4 signaling via 
promoting the TLR4 trafficking to lipid rafts an event that was attenuated by SsnB co-
incubation. These results were significant since it showed that SsnB can target an 
upstream molecular event in lipid raft trafficking of TLR4, considering the fact that leptin 
is not a ligand for TLR4 neither has it been shown to have structural similarity to a 
classical ligand of TLR4. We also have evidence from previous published reports from 
our lab that (i) leptin targets NADPH oxidase activation and (ii) NADPH oxidase drives 
TLR4 trafficking via peroxynitrite generation (40, 111). Based on these arguments we 
conducted studies to show the role of SsnB in NADPH oxidase activation. Our results of 
a significant increase in colocalization of gp91 (membrane subunit) and p47 phox 
(cytoplasmic subunit) in SH groups and its subsequent decrease in these events following 
SsnB administration indicated a novel role of SsnB apart from its proven role as an TLR4 
antagonist. Parallel to the in vivo data, Kupffer cells also showed significant attenuation 
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of NADPH oxidase activation following SsnB administration in response to both leptin 
and LPS. However it needs to be considered that NADPH oxidase activation primarily 
depends on membrane assembly of a number of subunits, p47 phox being one of them, a 
crucial element for NOX2 type NADPH oxidases(33, 46). Finally, SsnB-induced 
decrease in peroxynitrite marker 3-nitrotyrosine both in vivo and nitric oxide release in 
vitro showed a clear mechanistic connection between NADPH oxidation, increased 
nitrative stress and TLR4 activation following SsnB administration. It is worth 
mentioning here that peroxynitrite induced HMGB1, a TLR4 activator release has been 
shown(123). A decrease in peroxynitrite formation following NADPH oxidase inhibition 
by SsnB might be a parallel mechanism of SsnB amelioration of TLR4 pathway and 
subsequent decrease in early steatoheaptitic injury and inflammation in the liver. 
Taken together, our data describe a novel mechanistic role of SsnB in resolving 
NASH –induced inflammation primarily by blocking TLR4 lipid raft trafficking and 
NADPH oxidase activation. Future studies featuring SsnB binding kinetics to TLR4 or 
pathways unique to deactivation of NADPH oxidase might usher new light on probable 
therapeutic benefits of SsnB. 
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Figure 3.1 Sparstolonin B (SsnB) administration attenuates early steatohepatitic injury in 
obese mice. A: hematoxylin and eosin-stained paraffin-embedded liver tissue sections of 
steatosis (S; i), steatohepatitic injury (SH; ii), and SH+SsnB (iii) mice. Images were taken 
at ×10 magnification. B: serum levels of alanine aminotransferase (ALT) from S, SH, and 





Figure 3.2 SsnB administration to SH mice ameliorates proinflammatory cytokines and 
decreases M1 polarization. A: qRT-PCR analysis of mRNA expression of TNF-α, IFN-γ, 
IL-1β, and IL-23 from liver homogenates of S, SH, and SH+SsnB mice, normalized 
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against S (*P < 0.05). B: TNF-α (top) and IL-1β (bottom) immunoreactivity as shown by 
immunohistochemistry in liver slices from S (i), SH (ii), and SH+SsnB (iii) mouse 
samples. Images were taken at ×20 magnification. C: morphometric analysis of TNF-α 
immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05). D: morphometric analysis 
of IL-1β immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05). 
 
Figure 3.3 SsnB administration modulates Kupffer cell activation in early steatohepatitic 
injury. A:qRT-PCR analysis of mRNA expression of CD68 and monocyte 
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chemoattractant protein-1 (MCP1) from liver homogenates of S, SH, and SH+SsnB mice, 
normalized against S (*P < 0.05). B: MCP1 (top) and F4/80 (bottom) immunoreactivity 
as shown by immunohistochemistry in liver slices from S (i), SH (ii), and SH+SsnB (iii) 
mouse samples. Images were taken at ×20 magnification. C: morphometric analysis of 
MCP1 immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05). D: morphometric 




Figure 3.4. SsnB administration attenuates miR21 expression and repression of 
phosphatase and Tensin homologue (PTEN). A: qRTPCR analysis of miR21 expression 
of S, SH, SH+SsnB mice samples normalized against S (*P<0.05). B: Western blot 
analysis of β-actin and PTEN protein levels of S, SH, SH+SsnB sample1 and SH+SsnB 
sample2 respectively. C: Immunoreactive band analysis of PTEN normalized against β-





Figure 3.5 SsnB targets TLR4 trafficking to lipid rafts. A: immunofluorescence dual 
labeling depicting TLR4 (red)-flottilin1 (green) colocalization (yellow) in S (i) SH (ii), 
and SH+SsnB (iii) liver samples, taken at ×20 magnification. B: morphometric analysis 





Figure 3.6 SsnB targets LPS-induced TLR4 trafficking in Kupffer cells. A: 
immunofluorescence laser scanning images for colocalization of TLR4 (red) and 
flottilin2 (green) in rat Kupffer cells of the control (i–iv), LPS-treated (v–viii), and 
LPS+SsnB-treated (ix–xii) groups. Images in overlay panels on right depict 
colocalizations of TLR4-flottilin2, as revealed by the yellow regions. Images were taken 
at ×40 magnification. B: morphometric analysis of colocalization events in A, shown as 
colocalization events per 100 cells (*P < 0.05). C: immunofluorescence dual labeling of 
LPS-treated rat Kupffer cell sample depicting TLR4 (red)-flottilin2 (green) colocalization 




Figure 3.7 SsnB targets leptin-induced TLR4 trafficking in Kupffer cells. A: 
immunofluorescence laser scanning images for colocalization of TLR4 (red) and 
flottilin2 (green) in rat Kupffer cells of the Control (i–iv), leptin-treated (v–viii), and 
leptin+SsnB-treated (ix–xii) groups. Images in overlay panels on right depict 
colocalizations of TLR4-flottilin2, as revealed by the yellow regions. Images were taken 
at ×40 magnification. B: morphometric analysis of colocalization events in A, shown as 
colocalization events per 100 cells (*P < 0.05). C: immunofluorescence dual labeling of 
leptin-treated rat Kupffer cell sample depicting TLR4 (red)-flottilin2 (green) 





Figure 3.8 SsnB attenuates NADPH oxidase activation. A: immunofluorescence dual 
labeling depicting gp91phox (red)-p47phox (green) colocalization (yellow) in S (i), SH 
(ii), and SH+SsnB (iii) liver samples, taken at ×20 magnification. B: morphometric 
analysis of colocalization events in A, shown as colocalization events per 3× field (*P < 
0.05). C: immunofluorescence dual labeling of SH liver sample depicting gp91phox 
(red)-p47phox (green) colocalization (yellow) taken at ×60 (oil) magnification. D: 
immunofluorescence dual labeling of control (i), LPS (ii), LPS+SsnB (iii), control (iv), 
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leptin (v), and leptin+SsnB (vi) rat Kupffer cell samples depicting gp91phox (red)-
p47phox (green) colocalization (yellow), taken at ×40 magnification.
 
 
Figure 3.9 SsnB attenuates NADPH oxidase activation and peroxynitrite generation. A: 
3-nitrotyrosine immunoreactivity as shown by immunohistochemistry in liver slices from 
S (i), SH (ii), and SH+SsnB (iii) mouse samples. Images were taken at ×20 
magnification. B: morphometric analysis of 3-nitrotyrosine immunoreactivity in S, SH, 
and SH+SsnB groups (*P < 0.05). C: nitric oxide (nitrite) concentration measured by 
nitric oxide colorimetric assay in the supernatant collected from control, LPS-treated, and 





Figure 3.10 SsnB attenuates TLR ligand-induced macrophage activation, gene expression 
of P47phox, and gene expression and release of inflammatory cytokines in mouse 
primary hepatic macrophages. A: qRT-PCR analysis of mRNA expression of IL-1β, 
MCP1, and TNF-α from control (untreated), LPS-treated, and LPS+SsnB-treated mouse 
primary hepatic macrophages, normalized against control (*P < 0.05). B: TNF-α cytokine 
levels measured by ELISA from the supernatant collected from control, LPS-treated, and 
LPS+SsnB-treated mouse primary hepatic macrophages, normalized against control (*P 
< 0.05). C: qRT-PCR analysis of mRNA expression of p47phox from control (untreated), 
LPS-treated, and LPS+SsnB-treated mouse primary hepatic macrophages, normalized 






Figure 3.11 SsnB treatment does not reduce TLR4 gene expression or protein 
concentration. A: qRT-PCR analysis of mRNA expression of TLR4 from liver 
homogenates of S, SH, and SH+SsnB mice, normalized against S (*P < 0.05). B: qRT-
PCR analysis of mRNA expression of TLR4 from control (untreated), LPS-treated, and 
LPS+SsnB-treated mouse primary hepatic macrophages, normalized against control (*P 
< 0.05). C: Western blot analysis of β-actin and TLR4 protein levels in the liver 
homogenates of lean control (LC), LC+bromodichloromethane (BDCM), S, S+SsnB, SH, 
and SH+SsnB groups. D: immunoreactive band analysis of TLR4 normalized against β-







ADMINISTRATION OF SPARSTOLONIN B ATTENUATES HEPATIC 
FIBROSIS BY INHIBITING PROLIFERATION AND INDUCING 
APOPTOSIS IN HEPATIC STELLATE CELLS.3 
 
                                                          
3 Dattaroy D, Chandrashekaran V, Seth RK, Alhasson F, Fan D, Nagarkatti M, Nagarkatti 
Chatterjee S. To be submitted to British Journal of Pharmacology. 
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Abstract: 
This research unravels anti-fibrotic and anti-proliferative mechanisms of a plant derived 
TLR4 antagonist, Sparstolonin B (SsnB) in a Bromodichloromechane (BDCM) induced 
murine model of NASH and hepatic stellate cell culture. SsnB showed a promising role 
to lessen liver fibrosis by upregulating cell cycle inhibitory proteins and inhibiting 
fibrogenic cell proliferation. Mechanistically, SsnB, a TLR4 antagonist, decreased TLR4-
PI3k akt signaling by upregulating PTEN protein expression. It also decreased MDM2 
protein activation and increased p53 and p21 gene and protein expression. SsnB also 
downregulated pro-fibrogenic hedgehog signaling pathway, inhibited hepatic stellate cell 
proliferation and induced apoptosis in hepatic stellate cells. This anti-proliferative and 
pro-apoptotic properties of SsnB can be instrumental to ameliorate fibrotic lesions in liver 
when administered to murine model of NASH. 
4.1 INTRODUCTION 
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in liver 
which arises from hepatic fat accumulation (73). NASH is characterized by steatosis (fat 
deposition) in liver along with increased liver inflammation, fibrosis and progressive 
endothelial dysfunction, which can lead to cirrhosis and hepatocellular carcinoma (125, 
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126). NASH is a silent liver disease and patients generally feel well until they develop 
irreversible excessive liver damage. As there is almost no medication available to treat 
NASH related excessive liver damage, liver transplant can bring the only hope for 
survival-given that there is always a short supply of liver and liver transplant has been a 
challenge due to graft rejection, graft steatosis, infection during the transplantation etc. 
(127). The mortality of NASH affected patients can also increase by cardio-vascular 
damage (128).  As obesity is becoming a worldwide epidemic, the prevalence of Non 
Alcoholic Fatty Liver Disease (NAFLD) is increasing globally. NAFLD affected liver 
can progress into NASH like irreversible liver injury due to hepatic toxicity and imposes 
a major public health threat (127). Toll like receptors (TLRs) have been shown to play a 
major role in the pathogenesis of NASH and clinical studies show that endotoxemia as a 
result of leaky gut in NASH condition, can lead to TLR4 activation (24, 90). Increased 
oxidative stress, peroxinitrite formation, HMGB1 protein, Fibrinogen or other DAMPs 
(damage associated molecular patterns) associated with liver injury, can also act as 
ligands for TLR4 signaling (90). TLR4 activation can lead to increased JNK activation, 
which leads to inflammation, fibrosis, insulin resistance and other metabolic 
dysregulation during NASH (25). Abrogation of TLR4 trafficking to lipid rafts helps to 
decrease inflammation in murine NASH models and had better histological outcomes 
(90).  As TLR4 activation is a major event that leads to several inflammatory pathway 
activations and fibrogenesis, a potent TLR4 antagonist can be useful to treat such 
condition. Therefore, development of a novel therapeutic strategy to combat this disease 
is needed. In this research, we study the therapeutic role of a novel plant derived 
compound, Sparstolonin B (SsnB), on a toxin induced model of nonalcoholic 
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steatohepatitis. The purpose of the present study was to investigate the impact of SsnB on 
hepatic fibrosis in vivo and in vitro through assessment of the effects of SsnB on the 
proliferation of hepatic stellate cells, extracellular matrix deposition and pro-fibrogenic 
signaling pathways. We also wanted to find out the effect of SsnB on anti- proliferative 
proteins and hedgehog signaling pathway. 
4.2 MATERIALS AND METHODS 
Cell culture: Human immortalized stellate cell line (LX2) (kindly gifted by Dr. Ana Mae 
Diehl, Duke University) was grown in complete Dulbecco’s Modified Eagle’s Medium 
(DMEM, Corning, VA) with 10% fetal bovine serum (FBS, Atlas Biologicals, CO) and 
1x Penicillin-Streptomycin solution (Gibco, Life Technologies, NY) at 37°C in a 
humidified incubator with 5% CO2. Tissue culture plastic wares, HBSS buffer were 
purchased from Corning (Corning, VA). Sparstolonin B (SsnB) compound was kindly 
gifted by our collaborator Dr. Daping Fan (Cell Biology and Anatomy, University of 
South Carolina School of Medicine). Stock solution of SsnB was prepared in 100% 
dimethyl sulfoxide (DMSO). The final concentrations of SsnB on cells were 10µg/ml, 
0.1% DMSO and 100µg/ml, 0.1% DMSO respectively. The cells were plated on 6 
well/12 well plates using DMEM medium supplemented with 10% FBS. Before treating 
the cells with LPS (100ng/ml) and SsnB (10μM, 100μM), cells were cultured in DMEM 
with 2% FBS (overnight). All treatments are given for 24 hours in 2% FBS containing 
DMEM medium. Cells treated with 0.1% DMSO were used as control. Primary rat 
hepatic stellate cells (ScienCell Research Lab, Carlsbad, CA) were cultured in specific 
medium as instructed by the manufacturer, on poly-l-lysine (ScienCell Research Lab)-
coated 6well/ 12-well plates and incubated at 37°C in a humidified incubator with 5% 
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CO2 to initiate the culture. Treatments of LPS and SsnB were given as discussed above. 
All treated cells were subjected to mRNA and protein extraction. Maintaining 
aforementioned conditions, cells were plated on coverslips by putting coverslips on each 
well of 12 well plates and the cells adhered on coverslips were used for immune-
fluorescence dual labelling staining after the treatment. 
Mouse Models: Pathogen-free, male mice with C57BL/6J background (Jackson 
Laboratories, Bar Harbor, ME) were housed one per cage at 23-24°C with a 12-h/12-h 
light/dark cycle at libitum access to food and water. They were fed with 60% kcal high 
fat diet (Research Diets, New Brunswick, NJ) from 6 weeks until 16 weeks to generate a 
model of steatosis. We refer to this group as Control. A similar group of high fat fed mice 
were administered Bromodichloromethane BDCM (1mmol/kg, diluted in corn oil) though 
intraperitoneal injection, twice a week for 1 month to generate BDCM induced Non-
alcoholic steatohepatitis model of mice (NASH). BDCM and corn oil were purchased 
from Sigma-Aldrich (St. Louis, MO). A group of NASH mice were administered with 
SsnB (3mg/kg) intraperitoneally twice for 4 weeks (NASH+SsnB). NIH guideline for 
Humane Care and Use of Laboratory Animals and local IACUC standards were followed 
during animal handling. Animal experiments were approved by the University of South 
Carolina at Columbia. Upon completion of the treatment, all mice were sacrificed for 
liver tissues and serum samples for further experiments. 
Laboratory analysis 
Picrosirius red staining: Picrosirius red staining of formalin-fixed, paraffin embedded 
liver tissue sections (5-μm-thick) was done using a Nova ultra-sirius red stain kit 
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following manufacturer's instructions (IHC-World). Liver sections were observed under a 
×20 objective of a light microscope. Morphometric analysis of the stained regions of the 
tissue sections was performed using cellSens software (Olympus).  The degree of fibrosis 
was evaluated by following the METAVIR scoring system (F0: no fibrosis, F1: portal 
fibrosis without septum formation, F2: portal fibrosis with few septum formation, F3: 
portal fibrosis with several septum formations but no cirrhosis and F4: cirrhosis) on the 
basis of histological observation of the slides. 
Immunohistochemistry: Formalin-fixed, paraffin embedded liver tissue sections (5-μm-
thick) were subjected to de-paraffinization and antigen retrieval using standard protocol. 
Immunohistochemistry was performed on neutral buffer formalin (NBF) fixed liver 
tissues according to the protocol described in our early publication (19). Mouse 
monoclonal p53 (Cell Signaling Technology, MA) and p21 antibody (Santa cruz 
Biotechnology, TX) were used in recommended dilution. Rest of the experiment was 
processed as described in our previous publication (19).  
Immunofluorescence Microscopy 
In vivo: De-paraffinization and antigen retrieval was performed on formalin-fixed; 
paraffin embedded liver tissue sections (5-μm-thick) were done by using standard 
protocol. The primary antibodies MDM2 (Santa cruz Biotechnology, TX), Gli1 (Abcam, 
MA) were used in recommended dilutions. Species-specific secondary antibodies 
conjugated with Alexa Fluor 633 (Invitrogen, CA) were used against the appropriate 
primary antibodies. Rest of the experiment was processed as described in our previous 
publication (19).  
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In vitro: After completion of the treatments as previously stated, the cell attached 
coverslips were fixed and processed according to our previous publication (19). Cells 
were incubated with αSMA (Abcam, MA), p53 (CST, Danvers MA), and p21 (Santa cruz 
Biotechnology, TX) primary antibodies followed by species-specific Alexa Fluor 633 and 
488 (described above), for immunofluorescence dual-labeling staining. Alexa Fluor 633 
was used against p53 and p21 antibodies. Alexa Fluor 488 was used against αSMA 
antibody. ProLong Gold antifade reagent with DAPI (Life Technologies) was used to 
mount the stained cells attached on the coverslips and viewed under ×20 objective with 
an Olympus BX51 microscope. 
Quantitative Real-Time Polymerase Chain Reaction: Gene expression (mRNA) levels 
of rat hepatic stellate cell samples were measured by quantitative real-time reverse 
transcription-polymerase chain reaction (qRT-PCR) by following our routine lab 
protocol. The primers used for Real time PCR in 5’to 3’ orientations are rat p53 
(Forward: GCACGGCCTTTGTGGTAAAA,Reverse: TTTGCCAGGGCTGAGTAACC) 
ratp21(Forward:TGCCTTAGCCTTCATTCAGTGT,Reverse:TATCGAATTGCACGAG





AG, Reverse: TACCCCTTGAAGTGCTCGTACA). miR21 levels in tissues were 
measured as described in chapter2. 
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Western Blotting: Protein extraction and western blot from in vivo and in vitro samples 
were performed according to our lab protocol described elsewhere (129). Primary 
antibodies PTEN, β actin (Abcam, MA), p53 (Cell Signaling Technology, MA), Cyclin 
E, cleaved caspase3, total caspase3 and cleaved PARP1(Santa cruz Biotechnology, TX) 
were used at recommended dilutions, and compatible horseradish peroxidase-conjugated 
secondary antibodies were used. 
TUNEL assay: TUNEL based ApopTag® technology (EMD Millipore, MO) was used 
to detect apoptotic cells according to the manufacturer’s instructions. ProLong Gold 
Antifade Reagent (Life Technologies, Carlsbad, CA) with DAPI was used to mount the 
coverslips. The cells were imaged using immunofluorescence microscopy under ×20 
objective. 
Cell cycle analysis: After treating LX2 cells with LPS and/ SsnB (as described 
previously), the cells harvested and centrifuged for 10 minutes at 1000 rpm at 25°C in the 
medium. After aspirating the medium, cells were washed with PBS and again centrifuged 
for 10 minutes at 1000 rpm at 25°C. This step was repeated again and the cells were fixed 
with 70% ice cold ethanol (dropwise) for 30 minutes on ice. After fixing the cells, they 
were centrifuged again at 1000rpm for 5 minutes. Ethanol was aspirated and 1 ml of 
propidium iodide solution (containing RNase A and 0.1%Triton X) was added to the 
pellets and incubated in ice for 30 minutes on ice. The samples were analyzed by 
Beckman Coulter FC500 Flow Cytometer at Institutional Resource Facility at the 
University Of South Carolina School of Medicine. 
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Statistics: Data were represented as mean ± S.E. Statistical significance was calculated 
by Student's t test and the graphs were plotted using Origin (OriginLab Corporation, 
MA). p ≤ 0.05 was considered statistically significant. 
4.3 RESULTS:  
SsnB treatment ameliorates liver fibrosis in NASH mice. Picrosirius red stain is 
widely used to stain extracellular collagen matrix to detect fibrotic scar deposition in 
tissues. This staining is based on the firm binding of this stain’s sulfonic acid groups with 
the basic moieties of collagen fibers. Histological evaluation of mice liver tissues in 
NASH group shows increase deposition of collagen matrix and fibrosis compared to 
Control group. SsnB treated group (NASH+SsnB) showed significant reduction of 
fibrosis (Figure 4.1A, B). In Control group fibrosis scoring was F0 (no fibrosis), NASH 
group the fibrosis grade was F2 to F3 (periportal and septal fibrosis). Interestingly, fibrosis 
scoring in NASH+SsnB group was F0 to F1 (no fibrosis to mild fibrosis without septa) 
(Figure 4.1C).  
SsnB treatment decreased microRNA21 expression and upregulated PTEN protein 
expression in NASH liver. MicroRNA21 (miR21) is known to downregulate tumor 
suppressor protein PTEN (130). We have previously shown that SsnB administration 
decreases miR21 expression and induces PTEN expression in an early NASH model 
where diet induced obese mice were subjected to BDCM treatment for 1 week (19). 
Interestingly, we observed similar characteristics of SsnB when it was administered in 
our full-blown NASH model where diet induced obese mice were subjected to BDCM 
treatment for 4 weeks. We found that, SsnB treatment (NASH+SsnB group) significantly 
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reduces miR21 expression compared to NASH group (Figure 4.2 A). PTEN protein 
expression was decreased in NASH group compared to Control. However, SsnB 
treatment (NASH+SsnB) augmented PTEN expression (Figure 4.2 B) which 
complemented the reduced expression of miR21 in that group.  
SsnB treatment induced PTEN expression increases p53, p21 upregulation and 
decreases hedgehog signaling in liver. To detect the possible mechanism of PTEN 
induced expression of p53, we measured the immunoreactivity of MDM2 in paraffin 
embedded liver tissue sections though immunofluorescence microscopy. We observed 
significantly increased immunoreactivity of MDM2 in NASH liver section compared to 
Control liver. SsnB treated (NASH+SsnB) liver showed considerable decrease in MDM2 
immunoreactivity compared to NASH liver (Figure 4.3A). MDM2 is a known inhibitor of 
p53. Interestingly, Immunohistochemistry against p53 revealed decreased p53 protein 
expression in NASH mice liver in the sinusoidal area which was augmented with SsnB 
treatment (NASH+SsnB) (Figure 4.3B). Immunohistochemistry against p21 also reveals 
significant decrease in p21 immunoreactivity in NASH liver compared to Control. SsnB 
treatment significantly increased p21 immunoreactivity in the sinusoidal area of liver in 
NASH+SsnB group compared to NASH group (Figure 4.3C). Moreover, 
immunoreactivity against Gli1, a pro-fibrogenic nuclear transcription factor, was 
significantly increased in NASH liver section compared to Control liver. SsnB treated 
(NASH+SsnB) liver showed remarkable decrease in Gli1 immunoreactivity compared to 
NASH liver –as observed by immunofluorescence microscopy (Figure 4.3D). 
SsnB treatment decreased p53, p21 expression in vitro. To see whether SsnB can 
reduce expression of p53 and p21 in vitro as it does in vivo, we measured gene expression 
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of p53 and p21 through qRT PCR experiments in primary rat hepatic stellate cells. LPS 
treatment increased the gene expression of p53 and p21 compared to untreated or control 
cells. However, SsnB treatment was able to repress LPS induced upregulation of those 
genes (Figure 4.4A). Immunofluorescence microscopy also revealed increased 
immunoreactivity of p53 and p21 in SsnB treated primary rat hepatic stellate cells 
(LPS+SsnB) compared to only LPS treatment (Figure 4.4B, C respectively). 
SsnB treatment decreased gene expression of hedgehog signaling markers and 
reduces Cyclin E protein expression in vitro. To correlate SsnB induced repression of 
Gli1 (a hedgehog transcription factor) in vivo in an in vitro model, we measured gene 
expression of hedgehog signaling specific markers through qRT PCR experiments. LPS 
treatment increased the gene expression of Gli1, Gli2, Indian hedgehog (IHH) and 
Patched (Ptc) compared to untreated or control cells. However, SsnB treatment was able 
to repress LPS induced upregulation of those genes (Figure 4.5A). To see whether SsnB 
upregulation of PTEN, p53, p21 and repression of Gli1 alters proliferation of activated 
HSCs, we measured Cyclin E protein level from cell homogenates. LPS treatment had 
increased Cyclin E level compared to Control which decreased upon SsnB treatment 
(Figure 4.5B).  
SsnB treatment decreases proliferation and induces apoptosis in hepatic stellate 
cells. We performed flow cytometry to evaluate the effect of SsnB on hepatic stellate cell 
cycle progression. After treating the LX2 cells with vehicle, LPS and/ SsnB for 24 hours 
(as described previously), the cells were collected and stained with propidium iodide and 
then analyzed by Beckman Coulter FC500 Flow Cytometer. The resulting data clearly 
demonstrates that treatment of LX2 cells with SsnB (both 10 and 100μM concentrations) 
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induced accumulation of cells in G2/M phase (38.14% and 36.75% in SsnB 10μM and 
100μM respectively) compared to LPS treated group (27.55%) accompanied by a 
decreased number of cells in the G0-G1 phase (Figure 4.6 A). We also observed higher 
number of apoptotic nuclei in SsnB treated cells (LPS+SsnB) (Figure 4.6B). Western blot 
data clearly reveals increased p53 accumulation, increased cleaved caspase3 and cleaved 
PARP1 proteins in SsnB treated LX2 cells compared to LPS treated and control cells 
(Figure 4.6C), further establishing the pro-apoptotic role of SsnB. 
4.4 DISCUSSION: 
This study shows the anti-fibrotic and anti-proliferative mechanisms of plant derived 
TLR4 antagonist, Sparstolonin B (SsnB). Mechanistically, SsnB reduces TLR signaling 
by inhibiting MyD88 recruitment to TLR4 (28). Our initial histochemical data from 
picrosirius red stained liver slices proved that SsnB prevents NASH induced fibrotic 
scars. We wanted to explore whether SsnB inhibits fibrosis through inhibiting TLR4 
dependent pro-fibrogenic pathways. It is known that TLR4 signaling pathway activation 
can upregulate miR21 (131) which was reversed by SsnB, a TLR4 antagonist. PTEN 
(phosphatase and tensin homolog deleted on chromosome ten) is known to be a tumor 
suppressor. It can also inhibit PI3K/Akt signaling by dephosphorylating 
phosphatidylInositol (3,4,5) -trisphosphate (PIP3) at position 3 and also known to be 
involved in cell motility, proliferation, survival, metabolism and cellular architecture. It is 
known that PTEN can down regulate TLR4 induced pro-inflammatory pathways (132). 
Micro-RNA 21 is a known inhibitor of PTEN. Our study shows that PTEN expression is 
augmented in SsnB treated samples where miR21 was also downregulated. This proves 
that, SsnB can upregulate PTEN expression by inhibiting TLR4 induced miR21 
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expression in our NASH model. It is known that activated TLR4-PI3K pathway can 
induce p53 degradation by upregulating MDM2 (133). Recent research shows that 
senescence induction in fibrogenic cells by increasing p21, p53 can help to reduce 
excessive fibroblast proliferation and suppress hepatic tumor (134). However, no research 
has focused on the possible route of repressing hepatic stellate cell proliferation by 
antagonizing TLR4-PI3K/Akt-MDM2 signaling pathway by SsnB. We found that SsnB, 
a TLR4 antagonist can possibly affect TLR4-PI3K/Akt signaling by upregulating PTEN 
protein expression. Our data suggested that SsnB treatment downregulated MDM2 which 
was otherwise activated in NASH liver. Interestingly, we found that, p53 was upregulated 
in SsnB treatment, which proves that SsnB induced p53 activation by suppressing MDM2 
in a PTEN dependent mechanism (135). We also found upregulated p21 protein 
expression in SsnB treated liver (NASH+SsnB) compared to NASH liver. It is known 
that increased p53 induces p21 expression (136) which further supports our findings. 
Induction of p53 and p21 in fibrotic liver can be instrumental to decrease uncontrolled 
proliferation of fibroblasts. As uncontrolled HSC (a hepatic fibroblast) proliferation plays 
a major factor in hepatic fibrogenesis, we wanted to see whether SsnB induced activation 
of p53, p21 and decreased the proliferation of activated stellate cells. In vitro results 
showed that SsnB treatment increases mRNA and protein levels of p53 and p21 in HSC 
which was otherwise repressed by LPS-proving the anti-proliferative effect of SsnB. 
Hedgehog signaling plays a key role in liver fibrosis and is an important therapeutic 
target of anti-fibrotic drugs (137). Glioma-associated oncogene homolog1 (Gli1) is a 
transcription factor which is a downstream target of hedgehog signaling pathway (138). 
Previous research has shown that increased p53 expression is known to inhibit Gli1 
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(139).We found that SsnB treated mice liver tissue (NASH+SsnB) having upregulated 
p53 protein expression also had reduced expression of Gli1 compared to NASH mice 
liver. Activation of hepatic stellate cells (HSC) induces fibrosis in the liver and 
suppression of Hedgehog signaling in these cells is known to inhibit HSC activation 
(140).We found that SsnB treatment in HSC culture downregulates LPS induced 
activation of Hedgehog signal specific gene expression. 
Hedgehog signaling pathway is known to induce proliferation by upregulating 
Cyclin D and Cyclin E. Shh proliferative signaling stimulates or maintain cyclin gene 
expression and activity of the G1cyclin-Rb axis in proliferating cells (141, 142). Gli1 
inhibition is also known to inhibit cell growth and cell cycle progression at G2/M phase 
and induced apoptosis (143). Several researchers have already shown that SsnB can 
inhibit angiogenesis and proliferation of cancer cells by inhibiting mitotic cyclins (104, 
136). Similarly, our study found that SsnB treatment decreased Cyclin E activation in 
hepatic stellate cells. We also observed SsnB induced suppression of stellate cell 
proliferation at G2/M phase of cell cycle and apoptosis of hepatic stellate cells. Apoptosis 
induction in activated HSCs is one important therapeutic target to decrease HSC 
proliferation and hepatic fibrosis (144). Anti-apoptotic role of SsnB has previously been 
shown in different cell types (103). We observed significant number of apoptotic cells in 
SsnB treated group (LPS+SsnB) compared to untreated cells and LPS treated cells. 
Inhibition of hepatic stellate cell proliferation can reduce liver fibrosis and is a major 
therapeutic target of anti-fibrotic drugs (145, 146). Anti-proliferative and pro-apoptotic 
properties of SsnB make it a potential antifibrotic molecule. As In future, it will be 
interesting to see therapeutic role of SsnB in other in vivo models of liver fibrosis. Apart 
93 
 
from HSCs, portal fibroblasts and mesothelial cells are also known to be precursors of 
myofibroblasts. Hepatic cholangiocytes and hepatocytes can also acquire phenotype of 
myofibroblasts through a process of epithelial to mesenchymal transition in the liver 
(147, 148). It is important to elucidate the cell specific anti-fibrotic mechanisms of SsnB 
in future studies. 
In conclusion, SsnB inhibited liver fibrosis in murine NASH model and in HSC 
culture by modulating the expression of cell cycle related proteins and by downregulating 
the Hedgehog signaling pathway. These results suggest that SsnB is a promising 





Figure 4.1 SsnB treatment ameliorates liver fibrosis in NASH mice. A: Representative 
images of picrisirius red stain of Control, NASH and NASH+SsnB mice. Images were 
taken at ×20 magnification. (*P < 0.05).  B: Morphometric analysis of picrosirius red 
immunohistochemistry in liver slices from Control, NASH and NASH+SsnB mice 





Figure 4.2 SsnB treatment decreased microRNA21 expression and upregulated PTEN 
protein expression in NASH liver. A: qRT-PCR analysis of miR21 expression of Control, 
NASH, and NASH+SsnB mouse liver samples normalized against Control (*P < 0.05). 
B: Western blot analysis of β-actin and PTEN protein levels of Control, NASH, and 





Figure 4.3 SsnB treatment induced PTEN expression increases p53, p21 upregulation and 
decreases hedgehog signaling in liver. A: Representative images of MDM2 
immunoreactivity as shown by immunofluorescence microscopy on liver slices of 
Control, NASH and NASH+SsnB mice, taken at ×20 magnification using 
immunofluorescence microscopy. B: Representative images of p53 immunoreactivity as 
shown by immunohistochemistry on liver slices of Control, NASH and NASH+SsnB 
mice, taken at ×20 magnification.  C: Representative images of p21 
immunohistochemistry on liver slices of Control, NASH and NASH+SsnB mice, taken at 
×20 magnification.  D: Representative images of Gli1 immunoreactivity as shown by 
immunofluorescence microscopy on liver slices of Control, NASH and NASH+SsnB 




Figure 4.4 SsnB treatment decreased p53, p21 expression in vitro. A: qRT-PCR analysis 
of mRNA expression of p53 and p21 from control (untreated), LPS-treated, and 
LPS+SsnB(100μM) treated rat primary hepatic stellate cells, normalized against control 
(*P < 0.05). B. Immunofluorescence dual labeling of Control (untreated), LPS-treated, 
and LPS+SsnB(100μM) treated rat primary hepatic stellate cells depicting α-
SMA(green)-p53 (red) co-localization (yellow), taken at ×20 magnification. C. 
Immunoreactivity of p21 (red) in control (untreated), LPS-treated, and 
LPS+SsnB(100μM) treated rat primary hepatic stellate as shown by immunofluorescence 




Figure 4.5 SsnB treatment decreased gene expression of hedgehog signaling markers and 
reduces Cyclin E protein expression in vitro. A: qRT-PCR analysis of mRNA expression 
of Gli1, Gli2, IHH, Ptc from Control (untreated), LPS-treated, and LPS+SsnB(10μM 
/100μM) treated human immortalized hepatic stellate cells (LX2), normalized against 
control (*P < 0.05). B: Western blot analysis of Cyclin E and β-actin protein levels of 
Control (untreated), LPS-treated, and LPS+SsnB(100μM) treated human immortalized 




Figure 4.6 SsnB treatment decreases proliferation and induces apoptosis in hepatic 
stellate cells. A: Cell cycle analysis of untreated cells (control), cells treated with LPS 
and LPS+SsnB (10/100μM) Quantitation of the PI staining data is presented as the cell 
cycle distribution percentages. B: Apoptosis is indicated by TUNEL based ApopTag® 
technology (EMD Millipore, MO) which labels 3’-OH ends of DNA fragments by 
fluorescent antibody as detected by immunofluorescence microscopy in Control 
(untreated), LPS-treated, and LPS+SsnB(100μM) treated LX2 cells. C: Western blot 
analysis of p53,cleaved caspase3, total caspase3, cleaved PARP1 and β-actin protein 
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Abstract: 
Chronic hepatic inflammation can induce hepatic fibrosis and anti-fibrotic drug discovery 
is one of the major focuses to treat the pathogenesis of nonalcoholic steatohepatitis 
(NASH). We have previously shown that TLR4 activation increases inflammation and 
fibrosis in NASH. We have also observed anti-fibrotic and anti-proliferative activity of 
Sparstolonin B (SsnB). By using Bromodichloromethane (BDCM) induced model of 
NASH and a preventive model where mice having NASH were treated with SsnB, we 
aim to explore an alternative molecular mechanism through which SsnB can decrease 
fibrosis by antagonizing TLR4 induced TGFβ signaling pathway. Mechanistically, SsnB 
augmented BAMBI (a TGFβ pseudo-receptor) expression in mice liver by inhibiting 
TLR4 signaling pathway and thus reduced TGFβ signaling, resulting in decreased hepatic 
stellate cell activation and extracellular matrix deposition. In vitro experiments on hepatic 
stellate cells showed that SsnB increased gene and protein expression of BAMBI. It also 
decreased nuclear co-localization of phospho SMAD2/3 and SMAD4 protein and thus 
attenuated TGFβ signaling in vitro. We also observed a significant decrease in 
phosphorylation of SMAD2/3 protein, decreased STAT3 activation, alteration of focal 
adhesion protein and stress fiber disassembly upon SsnB administration in hepatic stellate 




5.1 INTRODUCTION:  
Nonalcoholic steatohepatitis (NASH) is a significant cause of mortality as it can cause 
liver fibrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma (149-151). 
During NASH associated chronic liver inflammation, activated hepatic stellate cells 
(HSCs) deposits excessive extracellular matrix proteins in the liver resulting in fibrotic 
scars (152). However, there is no therapy available to treat liver fibrosis in the patients 
with NASH except some life style modifications (153). Thus it is important to understand 
the molecular mechanisms of hepatic fibrosis to design therapeutic strategies to prevent 
and treat liver fibrosis. Different inflammatory signaling pathways are pivotal mediators 
of liver fibrogenesis and control the transition of quiescent hepatic stellate cells (HSC) to 
collagen-secreting myofibroblasts (154). Systemic levels of endotoxins have been 
detected in patients with liver cirrhosis (lipopolysaccharide, LPS) (155). Systemic 
endotoxins can be recognized by Toll like receptor 4 (TLR4) present in hepatocytes, 
kupffer cells, stellate cells, sinusoidal endothelial cells, biliary epithelial cells in the liver 
(156). Upon detecting the LPS or pathogen associated molecular patterns (PAMPS), the 
TLR4 receptors give rise to a myriad of inflammatory signaling pathways and increase 
the production of inflammatory cytokines, induce macrophage infiltration and increase 
oxidative stress (156-158).  Recent studies have indicated that tissue injury and matrix 
degradation can release some endogenous ligands also referred to as damaged associated 
molecular patterns (DAMPS) which can activate TLR4 signaling. Injured liver has 
augmented expression of TLR4 and its co-receptors which makes it more sensitive to  the 
cascade of inflammatory cell signaling pathway mediated by TLR4 signaling in the 
damaged tissue (27).  Induced TLR4 signaling can give rise to different downstream 
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factors like pro-inflammatory cytokines, chemotactic cytokines, reactive oxygen species 
(ROS), adhesion molecules, cell cycle regulating proteins, TGF-β1 pseudoreceptor 
BAMBI-which can give rise to pro-fibrogenic signals. Hepatic stellate cells along with 
kupffer cells, may be a target for TLR4 ligand induced liver injury and offer a direct 
connection between inflammatory and fibrotic liver damage (27). In our 
Bromodichloromethane (BDCM) induced model of NASH, we have previously shown 
that, activation of NADPH oxidase induces Toll like receptor 4 (TLR4) recruitment to the 
lipid rafts and thus potentiates inflammation (24). We have also shown that 
environmentally relevant doses of Bromodichloromethane (BDCM), induces fibrogenesis 
by a NADPH oxidase dependent pathway which increases microRNA21 activation, 
hepatic stellate cell activation and accelerates TGFβ signaling (20).  
Our collaborators have characterized a plant derived compound Sparstolonin B 
(SsnB) as a TLR4 antagonist. SsnB has also been shown to have anti-inflammatory, anti-
angiogenic, anti-proliferative and anti-oxidant properties (99, 102-104). We have already 
shown that SsnB decreases oxidative stress, kupffer cell activation, cytokine production 
and macrophage infiltration in an early model of NASH (19).  
In this study we test the hypothesis that administration of SsnB in NASH, 
abrogates TGFβ signaling and fibrogenesis by upregulating BAMBI in hepatic stellate 
cells. As TGFβ signaling activation can also induce JAK-STAT pathway and upregulates 
stress fiber assembly in myofibroblasts, we investigated the role of SsnB in alteration of 
those pathways (159, 160). In this study, we used a rodent model of NASH in 
Bromodichloromethane induced oxidative stress, lipotoxicity, and inflammation were 
used as “second/multiple hits” to cause NASH. We also used rat primary hepatic stellate 
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cells and human transformed hepatic stellate cells (LX2) as our in vitro models. Our data 
shows that SsnB can decrease myofibroblast proliferation through modulating multiple 
signaling pathways. 
5.2 MATERIALS AND METHODS:  
Cell culture: Human immortalized stellate cell line (LX2) and rat primary hepatic 
stellate cells were cultured as described in the previous chapter.  
Mouse Models: Pathogen-free, male mice with C57BL/6J background were treated as 
described in the previous chapter. 
Laboratory analysis 
Immunohistochemistry: Immunohistochemistry on formalin-fixed, paraffin embedded 
liver tissue sections (5-μm-thick) was performed as described in the previous chapter. 
Antibodies against fibronectin, BAMBI (Abcam, MA) were used in recommended 
dilution. Morphometric analysis of the immunoreactivity of tissue sections was 
performed using cellSens software (Olympus). 
Immunofluorescence 
In vivo: Formalin-fixed; paraffin embedded liver tissue sections (5-μm-thick) were 
processed as mentioned in the previous chapter. The primary antibodies against SMAD4 
(Santa cruz Biotechnology, TX), SMAD2/3, αSMA (Abcam, MA) were used in 
recommended dilutions. Species-specific secondary antibodies conjugated with Alexa 
Fluor 488 (Invitrogen, CA) were used against α-SMA and SMAD4 antibodies and 
secondary antibody conjugated with Alexa Fluor 633 was used against SMAD2/3 in 
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recommended dilutions. Rest of the experiments was performed as described elsewhere 
(17). 
In vitro: Cells were incubated with p-SMAD2/3 (Abcam, MA) and SMAD4 (Santa cruz 
Biotechnology, TX) primary antibodies followed by species-specific Alexa Fluor 633 and 
488 (described above), for immunofluorescence dual-labeling staining. Alexa Fluor 633 
was used against anti-p-SMAD2/3 antibody. Alexa Fluor 488 was used against anti-
SMAD4 antibody. Paxillin, αSMA and vinculin primary antibodies (Santa Cruz 
biotechnology, Inc. Santa Cruz, CA) were used in 1:250 dilutions. Species specific alexa 
Fluor 488 was used against αSMA antibody.Species specific alexa Fluor 633 was used 
against αSMA antibody. Rest of the experiment was performed as described in the 
previous chapter. 
Quantitative real-time polymerase chain reaction: Gene expression (mRNA) levels 
from mice liver tissue and hepatic stellate cell samples were measured by quantitative 
real-time reverse transcription-polymerase chain reaction (qRT-PCR) as described in 
previous chapter. The primers used for real time PCR in 5’to 3’ orientations are rat 
BAMBI (Forward: GCGGGGCGTCAATGGATCGC, Reverse: 
GAACTCAGAAGGCCTTCAAGG). 
Western blot: Western blot from in vivo and in vitro samples were performed according 
to our previous publication (18). Primary antibodies BAMBI, β actin, αSMA, CTGF 
(Abcam, MA), phospho SMAD2/4, total SMAD2/3 (Cell Signaling Technology, MA), 
phospho STAT3 (Santa Cruz biotechnology, Inc. Santa Cruz, CA) were used at 
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recommended dilutions, and compatible horseradish peroxidase-conjugated secondary 
antibodies were used. 
Statistics: As described previously. 
5.3 RESULTS: 
SsnB treatment decreases hepatic stellate cell activation in murine NASH: Hepatic 
stellate cells reside in the sinusoidal endothelium space of the liver and play a key role to 
induce fibrosis in the liver. Upon activation in NASH, the quiescent hepatic stellate cells 
transform into fibrogenic myofibroblasts and produce alpha smooth muscle actin protein 
(αSMA). αSMA is a reliable marker to detect hepatic stellate cell activation in the liver. 
We have already shown in the previous chapter that SsnB administration ameliorates 
fibrotic scars in NASH liver. Our immunofluorescence data showed that SsnB 
administration significantly decreased αSMA expression compared to NASH mouse liver 
(Figure 5.1 A, B).  
SsnB treatment in NASH mice upregulates BAMBI in liver: Studies have shown than 
TLR4 signaling activation can induce increased hepatic fibrosis by downregulating TGFβ 
pseudo receptor BAMBI. BAMBI is TGF-β type I receptor lacking an intracellular kinase 
domain. So it blocks signal transduction even after stimulation with TGF-beta 
superfamily ligands (161-163). Interestingly, immunohistochemistry of BAMBI on 
mouse liver sections showed that, BAMBI immunoreactivity was significantly decreased 
in NASH group compared to the Control group. However, NASH mice treated with SsnB 
(NASH+SsnB group) showed considerably increased immunoreactivity of BAMBI 
compared to NASH liver tissues (Figure 5.2 A, B). 
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SsnB treatment decreases fibronectin deposition in NASH liver: Fibronectin is an 
extracellular matrix (ECM) protein and its expression is stimulated by TGFβ signaling 
pathway (164). It is also known to play an important role in liver fibrosis (20). 
Interestingly, immunohistochemistry of fibronectin on mouse liver sections showed that, 
fibronectin immunoreactivity was significantly increased in NASH group in the 
sinusoidal area compared to the Control group. However, NASH mice treated with SsnB 
(NASH+SsnB group) showed considerably decreased immunoreactivity of fibronectin 
compared to NASH liver tissues (Figure 5.3A, B). 
SsnB upregulates BAMBI and decreases TGFβ signaling in vitro: Upon activated by 
TGFβ ligands and PAMPS, quiescent hepatic stellate cells (HSC) become profibrogenic 
myofibroblasts and are primarily responsible to induce hepatic fibrogenesis in NASH by 
producing excessive extracellular matrix proteins (165, 166). Interestingly, our in vitro 
data from rat primary hepatic stellate cells show that LPS treatment decreases BAMBI 
mRNA and protein expression compared to untreated or control cells. However, 
LPS+SsnB treated cells augmented BAMBI mRNA and protein expression compared to 
only LPS treated cells (Figure.5.4 A, B). SsnB treatment also decreased SMAD2/3, 
SMAD4 co-localization compared to only LPS treated LX2 cells (transformed human 
hepatic stellate cells) (Figure.5.4 C). Phosphorylation of SMAD2/3 protein was also 
decreased upon SsnB treatment compared to the LPS treated cells (Figure.5.4 D). 
SsnB downregulates STAT3 phosphorylation, decreases stellate cell activation and 
connective tissue growth factor in vitro: STAT3 inhibition is known to suppress 
hepatic stellate cell mediated fibrogenesis (167). STAT3 also cooperates with TGFβ1 in 
activation and anti-apoptosis of hepatic stellate cells (168). TGFβ is also known to 
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activate JAK1-STAT3 axis to augment liver fibrosis in coordination of SMAD mediated 
signaling pathway (159). We wanted to see whether SsnB modulates STAT3 activation in 
LX2 cells. Western blot experiment showed that SsnB treatment decreases STAT3 
phosphorylation, αSMA and CTGF protein expression compared to LPS treated LX2 
cells (Figure.5.5). 
SsnB treatment decreases focal adhesion associated adaptor protein expression and 
inhibits stress fiber formation in vitro: Paxillin is a multi-domain focal-adhesion 
adaptor protein located at the edge between the plasma membrane and cytoskeleton. It 
helps in the process of cell adhesion and acts as a scaffold to bind many signaling 
proteins to the cell membrane (169). Immunofluorescent imaging of paxillin (Figure 5.6 
A, B) shows that Control and LPS stimulated LX2 cells displayed heterogeneous 
adhesions which are large and elongated at the periphery of the cells. However, SsnB 
treatment on LX2 cells significantly decreases paxillin immunoreactivity at the periphery. 
The focal adhesion regions in SsnB treated cells are smaller than Control or LPS treated 
cells. While lower concentration of SsnB (10µM) decreased paxillin expression at the 
periphery of LX2 cells, higher concentration of SsnB further abrogated this focal 
adhesion adaptor protein expression and altered the cell morphology (Figure 5.6A,B). 
Maturation of focal adhesions fuels the assemblage of adhesion-associated actin bundles 
known as radial stress fibers (170). We have already seen in Figure5.5 that LPS treatment 
in LX2 cells increased αSMA protein expression compared to untreated or control cells. 
SsnB treatment decreased αSMA protein expression in LPS stimulated LX2 cells. In 
Figure 5.6C, immunofluorescent staining of αSMA specifically depicts the stress fiber 
morphology on LX2 cells. We observed that, SsnB treatment bocks the stress fiber 
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formation compared to LPS treated cells as indicated by immunoreactivity of αSMA 
(red) and vinculin (green). The cell morphology also changed upon SsnB treatment. They 
have smaller cell body, extended cell processes and they also lose stress fibers-similar to 
the quiescent stellate cells (171). 
.5.4 DISCUSSION:  
Intestinal microflora and a functional TLR4 (but not TLR2) are essential for hepatic 
fibrogenesis. TLR4 activation can induce hepatic stellate cell proliferation and 
extracellular matrix deposition in the liver, resulting in liver scarring in chronic liver 
diseases. Increased TLR4 signaling in hepatic stellate cells induces chemokine secretion 
and chemotaxis of macrophages but downregulates TGFβ pseudoreceptor bone 
morphogenetic protein and activin membrane bound inhibitor (BAMBI) and thus 
sensitizes the HSCs to TGFβ induced activation and myofibroblastic differentiation 
(161). We observed that SsnB treatment decreased hepatic stellate cell activation in vivo 
as indicated by αSMA immunoreactivity. TLR4 activation induces NF-κBp50:HDAC1 
interaction which represses transcription of BAMBI promoter (163). BAMBI is TGFβ 
type I receptor lacking an intracellular kinase domain. It blocks signal transduction even 
after stimulation with TGFβ superfamily ligands. Thus, decrease of BAMBI on hepatic 
stellate cells can increase TGFβ signaling and fibrogenesis (161, 163). As abrogation of 
TLR4 signaling induces BAMBI mediated inhibition of pro-fibrogenic TGFβ signaling 
pathway, a TLR4 antagonist like SsnB have the potency to decrease TLR4 mediated 
hepatic fibrosis. Here we found that SsnB treated NASH mice had upregulated BAMBI 
expression in liver which corresponds to decreased fibrogenesis.  Fibronectin, a 
multifunctional glycoprotein and extracellular matrix (ECM) component is produced by 
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hepatic stellate cells and is required to support other extracellular matrix protein assembly 
(65, 172). We have previously shown that, BDCM induced TGFβ signaling induces 
fibronectin protein expression in the NASH liver (20). Here we have observed that SsnB 
induced decreased stellate cell activation and TGFβ signaling through BAMBI 
upregulation which resulted in decreased fibronectin expression. From the histological 
data of picrosirius red stained liver slices in the previous chapter, we saw that SsnB 
treatment significantly decreased fibrotic scar deposition compared to NASH liver. 
Decreased fibronectin deposition upon SsnB treatment might be responsible in decreased 
collagen matrix accumulation in the liver. As hepatic stellate cells are the major 
fibrogenic cells in the liver, we wanted to see if SsnB mediated repression of TGFβ 
signaling by BAMBI upregulation is stellate cell dependent. Interestingly, we found that 
SsnB upregulates BAMBI in vitro. TGFβ signals by binding to TGFβRI an TGFβRII 
transmembrane proteins, each having serine/threonine kinase Ligand binding to this 
receptor protein complex, phosphorylates and activates TGFβRI by the cytoplasmic 
kinase domains of TGFβRII Activated TGFβRI phosphorylates SMAD2 and SMAD3 
which can form a complex with SMAD4 and assemble in the nucleus to initiate target 
gene expression in a SMAD dependent pathway (173). We found that SsnB decreased 
LPS induced TGFβ signaling by decreasing SMAD2/3 phosphorylation. SsnB induced 
reduction of TGFβ signaling was further confirmed by decreased co-localization of 
SMAD4 and phosphorylated SMAD2/3 in the nucleus in vitro. TGFβRI can also signal 
through non-SMAD pathways (174). It has been recently discovered that activated TGFβ 
signaling can also phosphorylate STAT3 and thus activates JAK1-STAT3 axis in 
coordination with SMAD pathway to induce TGFβ mediated fibrotic response in hepatic 
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stellate cells (159). Our in vitro data shows that SsnB decreased STAT3 phosphorylation 
in hepatic stellate cells and also downregulates αSMA and CTGF (connective tissue 
growth factor) protein levels. Both of these proteins are key players in fibrotic 
proliferation of myofibroblasts and are downstream mediators of TGFβ signaling (175). 
SsnB mediated downregulation of both αSMA and CTGF in hepatic stellate cells can be 
instrumental to decrease pro-fibrogenic cell proliferation. It is known that phosphorylated 
STAT3 localization to the focal adhesions increases the aggressive clinical behavior of 
proliferative cells. STAT3 is known to be required for cell motility (176). Focal adhesion 
plays an important role in liver fibrosis through activating hepatic stellate cells and 
induces TGFβ driven pro-fibrotic responses (144). αSMA is vital for focal adhesion 
maturation in myofibroblasts Activated myofibroblasts incorporate αSMA in stress 
fibers. αSMA has been found to decrease the intracellular mechanical stress on focal 
adhesions and induces their supermaturation (177).We found that, SsnB treatment 
changes the cell morphology of hepatic stellate cells. SsnB (100μM) treated LX2 cells 
became smaller, possessed less stress fibers and acquired a dendritic morphology. SsnB 
also induced αSMA filament disassembly and abolished focal adhesions. Inhibition focal 
adhesions and stress fibers of hepatic stellate cells by higher concentrations of SsnB can 
be crucial to inhibit stellate cell migration and it can also stop the stellate cells from 
acquiring a fibrogenic phenotype.  
To our knowledge, this is the first study reported to show the effects of SsnB on 
suppression of hepatic fibrogenesis through downregulation of a myriad of cell signaling 
pathways. In future, due to the strong anti-angiogenic and anti-proliferative properties of 
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SsnB, it will be interesting test the therapeutic effect of SsnB to improve the 





Figure 5.1 SsnB treatment decreases hepatic stellate cell activation in murine NASH. A: 
Representative images of αSMA immunoreactivity as shown by immunofluorescence 
microscopy on liver slices of Control, NASH and NASH+SsnB mice, taken at ×20 
magnification using immunofluorescence microscopy. B: Morphometric analysis of 





Figure 5.2 SsnB treatment in NASH mice upregulates BAMBI in liver. A: Representative 
images of BAMBI immunoreactivity as shown by immunohistochemistry on liver slices 
of Control, NASH and NASH+SsnB mice, taken at ×20 magnification. B: Morphometric 





Figure 5.3 SsnB treatment decreases fibronectin deposition in NASH liver. A: 
Representative images of fibronectin immunoreactivity as shown by 
immunohistochemistry on liver slices of Control, NASH and NASH+SsnB mice, taken at 






Figure 5.4 SsnB upregulates BAMBI and decreases TGFβ signaling in vitro. A: qRT-
PCR analysis of mRNA expression of BAMBI from control (untreated), LPS-treated, and 
LPS+SsnB treated rat primary hepatic stellate cells, normalized against control (*P < 
0.05). B. Western blot analysis of β-actin and BAMBI protein levels of Control 
(untreated), LPS-treated, and LPS+SsnB treated rat primary hepatic stellate cells. C. 
Immunofluorescence dual labeling depicting SMAD2/3 (red)-SMAD4 (green) co-
localization (yellow) on Control (untreated), LPS-treated, and LPS+SsnB treated human 
immortalized hepatic stellate cells (LX2) taken at ×40 magnification. D. Western blot 
analysis of phospho SMAD2/3, total SMAD2/3 and β actin protein levels of Control 
(untreated), LPS-treated, and LPS+SsnB (10/100µM) treated human immortalized 




Figure 5.5 SsnB downregulates STAT3 phosphorylation, decreases stellate cell activation 
and connective tissue growth factor in vitro. A: Western blot analysis of phospho STAT3, 
αSMA, CTGF and β actin protein levels of Control (untreated), LPS-treated, and 





Figure 5.6 SsnB treatment decreases focal adhesion protein expression and inhibits stress 
fiber formation in vitro. A: Immunofluorescence microscopy depicting paxillin (green) 
immunoreactivity in Control (untreated), LPS-treated, and LPS+SsnB(10/100µM) treated 
human immortalized hepatic stellate cells (LX2) taken at ×20 magnification B: 
Immunofluorescence microscopy depicting paxillin (green) immunoreactivity at ×40 
magnification in Control (untreated), LPS-treated, and LPS+SsnB(100µM) treated human 
immortalized hepatic stellate cells (LX2). Paxillin immunoreactivity (on the edges of the 
cells) is pointed by white arrows. C: Immunofluorescence dual labeling depicting 
αSMA(red)-Vinculin(green) on Control (untreated), LPS-treated, and 
LPS+SsnB(100µM) treated human immortalized hepatic stellate cells (LX2) taken at ×40 
magnification. αSMA immunoreactivity (as stress fibers) is pointed by white arrows. 






Nonalcoholic steatohepatitis (NASH) is a hepatic manifestation of metabolic syndrome 
which arises due to fat accumulation in liver. According to the most recognized model of 
“two-hits” or "multiple-hits” hypothesis of NASH, the primary hit comes from steatosis 
or lipid accumulation in the liver. The primary hit makes the liver more vulnerable to the 
secondary hits- like oxidative stress, subsequent lipid peroxidation, proinflamatory 
cytokines, adipokines and mitochondrial dysfunction. Together they are able to induce 
hepatic injury, severe inflammation and fibrosis in the liver (105, 178). Our lab has 
previously established that chronic low exposure to Bromodichloromethane (BDCM), a 
drinking water disinfection byproduct, causes nonalcoholic steatohepatitis (NASH) in a 
diet induced obese mice model where CYP2E1 mediated oxidative stress plays an 
important pathogenic role as a “second hit” (17) of NASH progression. I have studied 
molecular mechanisms by which BDCM induces hepatic inflammation and fibrosis. I 
have also looked at the anti-inflammatory and anti-fibrotic effects of a plant derived 
compound called Sparstolonin B, in vivo and in vitro models of hepatic injury. 
It is known that upregulation of NADPH oxidase (NOX), plays a major role in the 
activation process of hepatic myofibroblasts (179). However, the molecular mechanisms 
that link NADPH oxidase activation and upregulation of transforming growth factor
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 (TGFβ) signaling have been indistinct. Here, I have investigated the role of leptin-
mediated upregulation of NADPH oxidase and increased expression of microRNA 21 
(miR21) in hepatic fibrogenesis. Human NASH liver samples and a high-fat (60% kcal) 
diet-fed BDCM induced mouse NASH model were used for this study. Mice lacking in 
genes for p47phox, leptin and miR21 were used to prove the role of the leptin-NADPH 
oxidase-miR21 axis. Our results showed that oxidative stress was significantly increased 
in wild-type (C57BL/6 background) mice NASH model and human NASH liver samples. 
These samples also showed increased p47phox expression, induced NF-κB activation and 
increased miR21. Both wild type mice NASH model and human NASH liver samples 
showed increased TGFβ signaling, increased SMAD2/3 and SMAD4 co-localizations in 
the nucleus, increased immunoreactivity against extracellular matrix markers with an 
associated decrease in protein concentration of SMAD7, an antagonist of TGFβ signaling 
pathway. NADPH oxidase activation has been shown in fibrogenesis, however, there are 
no known studies linking NADPH oxidase-based oxidative stress signaling through pro-
fibrogenic miRNA expression and TGFβ signaling. This was the first study that 
elucidates the role of leptin mediated NADPH oxidase in the induction of miR21 in a 
murine NASH model as well as in human NASH liver samples (20). This research 
revealed some interesting mechanisms by which leptin-mir21 axis can induce hepatic 
injury by increasing inflammation, oxidative stress and fibrogenesis in NASH liver. Thus, 
mir21 can be considered as an important therapeutic target to mitigate NASH 
pathogenesis. 
Apart from exploring the basic mechanisms of hepatic injury in NASH, I have 
also investigated the hepatoprotective effects of Sparstolonin B (SsnB), an isocoumarin 
121 
 
isolated from Sparganium stoloniferum. This herb has historically been used in traditional 
Chinese herbal medicine as an anti-inflammatory, anti-cancer drug.  SsnB has been 
shown to disrupt TLR4 and TLR2 dependent downstream signaling pathways, including 
NfkB and MAPK (102). We are the first group to test the therapeutic effect of this 
compound in NASH. Interestingly, I observed that SsnB administration attenuated 
hepatic inflammation and serum alanine aminotransferase (ALT) in a BDCM induced 
mice model of early NASH. SsnB also showed decreased gene and protein expression of 
proinflammatory cytokines in vivo and in vitro. Kupffer cell activation was also 
significantly decreased by SsnB as evidenced by reduction in CD68 and monocyte 
chemoattractant protein 1 (MCP1) mRNA and protein levels with associated inhibition of 
macrophage infiltration in liver. Mechanistically, SsnB abrogated TLR4 trafficking to the 
lipid rafts, as evidenced by the co-localization of TLR4 and lipid raft marker flotillin in 
liver tissues and immortalized kupffer cells. As we have shown previously that NADPH 
oxidase drives TLR4 trafficking in NASH, we studied the role of SsnB in modulating this 
pathway. SsnB also seems to inhibit peroxynitrite mediated oxidative stress by 
deactivating NADPH oxidase (19). 
SsnB has also been characterized as anti-proliferative drug which induced cell 
cycle arrest in neuroblastoma cells. It could also induce apoptosis and promote cell death 
in cancer cells (103). I have established anti-fibrotic and anti-proliferative mechanisms of 
SsnB in a BDCM induced murine model of NASH and in hepatic stellate cell (HSC) 
culture. I have found that SsnB shows a promising role to decrease liver fibrosis by 
reducing TLR4-PI3K mediated pro-inflammatory signaling pathway. It is known that 
activated TLR4-PI3K pathway can induce p53 degradation by upregulating MDM2 
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(133). Recent research shows that senescence induction in fibrogenic cells by the increase 
of p21, p53 can help to reduce excessive fibroblast proliferation and suppress hepatic 
tumor (134). However, no research has focused on the possible mechanism of senescence 
induction by antagonizing TLR4-PI3k -MDM2 signaling. My work shows that SsnB 
antagonizes TLR4-PI3k signaling by upregulating PTEN protein expression. It further 
lowers MDM2 activation and thus increases p53 and p21 gene and protein expression. 
SsnB also decreased TGFβ signaling by upregulating TGFβ pseudo-receptor BAMBI in 
vivo. As HSCs are the major fibrogenic cells in the liver, I wanted to see the therapeutic 
effect of SsnB on these cells. SsnB treatment also downregulated gene expression of pro-
fibrogenic hedgehog signaling pathway markers (Ihh, Shh, Gli1, Gli2) in HSCs. SsnB 
also arrested cell cycle at G2-M phase and induced apoptosis in HSCs. In vitro 
experiments on rat and human HSCs showed that SsnB treatment increased gene and 
protein expression of BAMBI and decreased nuclear co-localization of phospho 
SMAD2/3 and SMAD4 protein. A decrease in phosphorylated SMAD2/3 protein upon 
SsnB administration in HSCs further confirms the inhibitory effects of SsnB on TGFβ 
signaling. SsnB decreased STAT3 phosphorylation, downregulated hepatic stellate cell 
activation and extracellular matrix protein synthesis. We also found that SsnB diminishes 
the fibroblastic morphology of hepatic stellate cells by downregulating focal adhesion 
associated adaptor protein and attenuating the stress fiber formation. this research 
unravels a novel mechanistic approach to diminish fibrogenesis in NASH through 
inhibiting a myriad of pro-fibrogenic signaling pathways by SsnB.  
Although our research has shown promising anti-inflammatory and anti-fibrotic 
potential of SsnB, our results are constrained within limited scope of experiments. It will 
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be interesting to establish a therapeutic model of NASH where mice with full blown 
NASH will be administered with SsnB after the disease development. To increase 
absorption and bioavailability of SsnB, it will be interesting if SsnB can be coupled with 
nanoparticle to facilitate targeted delivery and controlled release. SsnB mediated 
alteration of metabolic pathways and steatosis regulation will be worth exploring. As 
SsnB has shown itself to be a strong anti-angiogenic and anti-proliferative molecule, it 
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